var title_f30_61_31696="Gram stain sputum 10C answer";
var content_f30_61_31696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nocardia on Sabouraud's agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On Sabouraud's agar, Nocardia grows slowly as a spidery, dry, sometimes pigmented colony.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31696=[""].join("\n");
var outline_f30_61_31696=null;
var title_f30_61_31697="Stage I lateral condyle fracture 1";
var content_f30_61_31697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Stage I lateral condyle elbow fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Injury film of a 7-year-old with an undisclosed fracture of the lateral condyle (black arrows). Attention was drawn to the location of the fracture because of extensive soft tissue swelling on the lateral aspect (white arrows). Panel B) Because of the extensive soft tissue injury, there was little intrinsic stability, allowing the fracture to become displaced at 7 days (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31697=[""].join("\n");
var outline_f30_61_31697=null;
var title_f30_61_31698="Miliary tuberculosis CXR";
var content_f30_61_31698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of miliary tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A full PA radiograph of the chest shows diffuse involvement (left). The right panel is magnified, illustrating the reticulonodular pattern of miliary tuberculosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jo-Anne Shepard, MD, Massachusetts General Hospital, Boston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31698=[""].join("\n");
var outline_f30_61_31698=null;
var title_f30_61_31699="Butenafine: Drug information";
var content_f30_61_31699=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Butenafine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/30/26083?source=see_link\">",
"    see \"Butenafine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotrimin&reg; ultra&trade; [OTC];",
"     </li>",
"     <li>",
"      Mentax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea corporis, tinea cruris",
"     </b>",
"     (Lotrimin&reg; ultra&trade;): Apply once daily for 2 weeks to affected area and surrounding skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea versicolor",
"     </b>",
"     (Mentax&reg;): Apply once daily for 2 weeks to affected area and surrounding skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea pedis",
"     </b>",
"     (Lotrimin&reg; ultra&trade;): Apply to affected skin between and around the toes, twice daily for 1 week, or once daily for 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F143762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin&reg; ultra&trade;: 1% (12 g, 24 g) [contains benzyl alcohol, sodium benzoate; for athlete's foot]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin&reg; ultra&trade;: 1% (12 g) [contains benzyl alcohol, sodium benzoate; for jock itch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mentax&reg;: 1% (15 g, 30 g) [contains benzyl alcohol, sodium benzoate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5194003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply to clean, dry skin. Avoid occlusive dressings.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lotrimin may be confused with Lotrisone&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     &ge;1%: Dermatologic: Burning, contact dermatitis, erythema, irritation, pruritus, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to butenafine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allylamine antifungal hypersensitivity: Use caution in patients sensitive to allylamine antifungals (eg naftifine, terbinafine); cross sensitivity to butenafine may exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunocompromised patients: Has not been studied in immunocompromised patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes, mouth, nose, or other mucous membranes. Do not use on nails or scalp.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5194002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if butenafine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering butenafine to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lotrimin Ultra External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (12 g): $8.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Mentax External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $94.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F143738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Culture and KOH exam, clinical signs of tinea pedis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ankorme (TW);",
"     </li>",
"     <li>",
"      Bunafine (TW);",
"     </li>",
"     <li>",
"      Butefin (TW);",
"     </li>",
"     <li>",
"      Butop (IN);",
"     </li>",
"     <li>",
"      Dermacom (CN);",
"     </li>",
"     <li>",
"      Funcid (PH);",
"     </li>",
"     <li>",
"      Mentax (EE, IL, JP, KP, TW);",
"     </li>",
"     <li>",
"      Sanmasu (TW);",
"     </li>",
"     <li>",
"      Sergen (TW);",
"     </li>",
"     <li>",
"      Te Li Da (CL);",
"     </li>",
"     <li>",
"      Zaxem (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Butenafine exerts fungicidal activity against dermatophytes (eg trichophyton, epidermophyton) by blocking squalene epoxidation, resulting in inhibition of ergosterol synthesis and subsequent weakening of fungal cell membranes.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal systemic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via hydroxylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Alpha: 35 hours; Beta: &gt;150 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 6-15 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Greer DL, Weiss J, Rodriguez DA, et al, &ldquo;A Randomized Trial to Assess Once-Daily Topical Treatment of Tinea Corporis With Butenafine, a New Antifungal Agent,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1997, 37(2 Pt 1):231-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31699/abstract-text/9270509/pubmed\" id=\"9270509\" target=\"_blank\">",
"        9270509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McNeely W and Spencer CM, &ldquo;Butenafine,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 55(3):405-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31699/abstract-text/9530545/pubmed\" id=\"9530545\" target=\"_blank\">",
"        9530545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reyes BA, Beutner KR, Cullen SI, et al, &ldquo;Butenafine, a Fungicidal Benzylamine Derivative, Used Once Daily for the Treatment of Interdigital Tinea Pedis,&rdquo;",
"      <i>",
"       Int J Dermatol",
"      </i>",
"      , 1998, 37(6):450-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31699/abstract-text/9646136/pubmed\" id=\"9646136\" target=\"_blank\">",
"        9646136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Syed TA, Ahmadpour OA, Ahmad SA, et al, &ldquo;Management of Toenail Onychomycosis With 2% Butenafine and 20% Urea Cream: A Placebo-Controlled, Double-Blind Study,&rdquo;",
"      <i>",
"       J Dermatol",
"      </i>",
"      , 1998, 25(10):648-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31699/abstract-text/9830263/pubmed\" id=\"9830263\" target=\"_blank\">",
"        9830263",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Topical Butenafine for Tinea Pedis,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1997, 39(1004):63-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31699/abstract-text/9217695/pubmed\" id=\"9217695\" target=\"_blank\">",
"        9217695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tschen E, Elewski B, Gorsulowsky DC, et al, &ldquo;Treatment of Interdigital Tinea Pedis With a 4-Week Once-Daily Regimen of Butenafine Hydrochloride 1% Cream,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1997, 36(2 Pt 1):S9-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31699/abstract-text/9039199/pubmed\" id=\"9039199\" target=\"_blank\">",
"        9039199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9177 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31699=[""].join("\n");
var outline_f30_61_31699=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143754\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143766\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143755\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143762\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143756\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143740\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143727\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5194003\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143741\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143772\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143764\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143744\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143731\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298916\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218718\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143736\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5194002\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143757\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265708\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143746\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143738\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539825\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143730\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143743\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9177\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9177|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/30/26083?source=related_link\">",
"      Butenafine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_61_31700="Barker method of temporary abdominal closure in situ";
var content_f30_61_31700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Barker method of temporary abdominal closure in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31700=[""].join("\n");
var outline_f30_61_31700=null;
var title_f30_61_31701="Cefuroxime: Pediatric drug information";
var content_f30_61_31701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefuroxime: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"    see \"Cefuroxime: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/55/29556?source=see_link\">",
"    see \"Cefuroxime: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ceftin&reg;;",
"     </li>",
"     <li>",
"      Zinacef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefuroxime&reg;;",
"     </li>",
"     <li>",
"      Auro-Cefuroxime;",
"     </li>",
"     <li>",
"      Ceftin&reg;;",
"     </li>",
"     <li>",
"      Cefuroxime For Injection;",
"     </li>",
"     <li>",
"      Cefuroxime For Injection, USP;",
"     </li>",
"     <li>",
"      PRO-Cefuroxime;",
"     </li>",
"     <li>",
"      ratio-Cefuroxime",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Second Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.M., I.V.: 50-100 mg/kg/day divided every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"      see \"Cefuroxime: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 75-150 mg/kg/day divided every 8 hours; maximum dose: 6 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis: Not recommended due to reports of treatment failures and slower bacteriologic response time (doses of 200-240 mg/kg/day divided every 6-8 hours have been used); maximum dose: 9 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 750 mg to 1.5 g/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"     <b>",
"      Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &ge;3 months to Children 12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pharyngitis, tonsillitis: Suspension: 20 mg/kg/day (maximum dose: 500 mg/day) in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute otitis media, acute bacterial maxillary sinusitis, impetigo:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Suspension: 30 mg/kg/day (maximum dose: 1 g/day) in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablet: 250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults: 250-500 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Uncomplicated urinary tract infection: 125-250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Uncomplicated gonorrhea: Single 1 g dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Early Lyme disease: 500 mg twice daily for 20 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-20 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic solution, as sodium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zinacef&reg;: 750 mg (50 mL); 1.5 g (50 mL) [contains sodium 4.8 mEq (111 mg) per 750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 750 mg, 1.5 g, 7.5 g, 75 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zinacef&reg;: 750 mg, 1.5 g, 7.5 g [DSC] [contains sodium ~1.8 mEq (41 mg) per 750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as axetil [strength expressed as base]: 125 mg/5 mL (100 mL); 250 mg/5 mL (50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ceftin&reg;: 125 mg/5 mL (100 mL) [contains phenylalanine 11.8 mg/5 mL; tutti frutti flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ceftin&reg;: 250 mg/5 mL (50 mL, 100 mL) [contains phenylalanine 25.2 mg/5 mL; tutti frutti flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as axetil [strength expressed as base]: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ceftin&reg;: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Cefuroxime axetil suspension must be administered with food; shake suspension well before use; tablets may be administered with or without food; administer with food to decrease GI upset; avoid crushing the tablet due to its bitter taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IVP: Administer over 3-5 minutes at a maximum concentration of 100 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. intermittent infusion: Administer over 15-30 minutes at a final concentration for administration &le;30 mg/mL; in fluid restricted patients, a concentration of 137 mg/mL may be administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: I.M. injection is less painful when administered as an injectable suspension rather than a solution, and is less painful when administered into the buttock rather than the thigh",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F148359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, anidulafungin, atracurium, aztreonam, bivalirudin, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, etoposide phosphate, famotidine, fenoldopam, fentanyl, fludarabine, foscarnet, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, linezolid, melphalan, meperidine, milrinone, morphine, ondansetron, pancuronium, pemetrexed, propofol, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Azithromycin, filgrastim, fluconazole, midazolam, pantoprazole, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amiodarone, cisatracurium, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted injectable solution (100 mg/mL) or injectable suspension (200-220 mg/mL) is stable for 24 hours at room temperature or 48 hours when refrigerated; reconstituted oral suspension can be stored in the refrigerator or at room temperature; discard after 10 days",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A second generation cephalosporin useful in infections caused by susceptible staphylococci, group B streptococci, pneumococci,",
"     <i>",
"      H. influenzae",
"     </i>",
"     (type A and B),",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     , and",
"     <i>",
"      Klebsiella",
"     </i>",
"     ; treatment of susceptible infections of the upper and lower respiratory tract, otitis media, acute bacterial maxillary sinusitis, urinary tract, skin and soft tissue, bone and joint, and sepsis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cefuroxime may be confused with cefotaxime, cefprozil, deferoxamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ceftin&reg; may be confused with Cefzil&reg;, Cipro&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zinacef&reg; may be confused with Zithromax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ceftin [U.S., Canada] may be confused with Cefiton brand name for cefixime [Portugal]; Ceftim brand name for ceftazidime [Portugal]; Ceftime brand name for ceftazidime [Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F148358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Diaper rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Alkaline phosphatase increased, lactate dehydrogenase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (duration-dependent), nausea/vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemoglobin and hematocrit decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, BUN increased, chest pain, cholestasis, colitis, creatinine increased, dyspnea, erythema multiforme, fever, GI bleeding,  hemolytic anemia, hepatitis, hives, hyperbilirubinemia, hypersensitivity, interstitial nephritis, jaundice, leukopenia,  neutropenia, pain at injection site, pancytopenia, positive Coombs test, prolonged PT/INR, pseudomembranous colitis, rash, renal dysfunction, seizure, Stevens-Johnson syndrome, stomach cramps, tachycardia, thrombocytopenia (rare), tongue swelling, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, asterixis, colitis, encephalopathy, hemorrhage, neuromuscular excitability, serum-sickness reactions, superinfection, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefuroxime, any component, or cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with renal impairment; use with caution in patients with history of colitis or history of penicillin hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in superinfection; patients with renal or hepatic impairment, poor nutritional state, patients previously stabilized on anticoagulant therapy, or who have received a prolonged course of antimicrobial therapy are at risk for developing a fall in prothrombin activity. Monitor prothrombin time and consider administering vitamin K if indicated. Safety and efficacy in infants &lt;3 months of age have not been established; do not use in patients with immediate-type hypersensitivity reactions to penicillin",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Cefuroxime. Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food and milk increase bioavailability and peak levels",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5193889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Cefuroxime crosses the placenta and reaches the cord serum and amniotic fluid. Placental transfer is decreased in the presence of oligohydramnios. Several studies have failed to identify an increased teratogenic risk to the fetus following maternal cefuroxime use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     During pregnancy, mean plasma concentrations of cefuroxime are 50% lower, the AUC is 25% lower, and the plasma half-life is shorter than nonpregnant values. At term, plasma half-life is similar to nonpregnant values and peak maternal concentrations after I.M. administration are slightly decreased. Pregnancy does not alter the volume of distribution. Cefuroxime is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; number and type of stools/day for diarrhea; and prothrombin time",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis resulting in cell wall death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Increased when given with or shortly after food or infant formula",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into bronchial secretions, synovial and pericardial fluid, kidneys, heart, liver, bone and bile; penetrates into CSF with inflamed meninges; crosses the placenta; excreted into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 33% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral cefuroxime axetil tablets: 37% to 52%; cefuroxime axetil suspension is less bioavailable than the tablet (91% of the AUC for tablets)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;3 days: 5.1-5.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-14 days: 2-4.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3-4 weeks: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-2 hours (prolonged in renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Within 15-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily 66% to 100% as unchanged drug in urine by both glomerular filtration and tubular secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Dialyzable",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31701/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Louvois J, Mulhall A, and Hurley R, &ldquo;Cefuroxime in the Treatment of Neonates,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1982, 57(1):59-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31701/abstract-text/7065695 /pubmed\" id=\"7065695 \" target=\"_blank\">",
"        7065695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gooch WM 3rd, Blair E, Puopolo A, et al, &ldquo;Effectiveness of Five Days of Therapy With Cefuroxime Axetil Suspension for Treatment of Acute Otitis Media,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1996, 15(2):157-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31701/abstract-text/8822290/pubmed\" id=\"8822290\" target=\"_blank\">",
"        8822290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JD, &ldquo;Cefuroxime: A Cephalosporin With Unique Applicability to Pediatric Practice,&rdquo;",
"      <i>",
"       Pediatr Infect Dis",
"      </i>",
"      , 1983, 2(5):394-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31701/abstract-text/ 6356062 /pubmed\" id=\" 6356062 \" target=\"_blank\">",
"        6356062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thoene DE and Johnson CE, &ldquo;Pharmacotherapy of Otitis Media,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(3):212-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/61/31701/abstract-text/1862012/pubmed\" id=\"1862012\" target=\"_blank\">",
"        1862012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13137 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31701=[""].join("\n");
var outline_f30_61_31701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148305\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046145\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442230\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046138\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148279\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148263\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046149\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148359\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046142\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046148\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148361\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148358\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046152\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046137\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046136\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298999\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148272\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046155\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148275\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5193889\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046144\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046135\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046151\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13137\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13137|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=related_link\">",
"      Cefuroxime: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/55/29556?source=related_link\">",
"      Cefuroxime: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_61_31702="Gangrenous myositis Light";
var content_f30_61_31702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Spontaneous gangrenous myositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Muscle biopsy from a patient with spontaneous gangrenous myositis due to Streptococcus pyogenes (group A streptococcus). Left panel: Necrotic muscle fibers with numerous infiltrating leukocytes. Right panel: Gram stain shows Gram positive bacteria in an area of muscle necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Larry M Baddour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31702=[""].join("\n");
var outline_f30_61_31702=null;
var title_f30_61_31703="Determinants of glucocorticoid dosing";
var content_f30_61_31703=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Determinants of glucocorticoid dosing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31703/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31703/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31703/contributors\">",
"     Kenneth G Saag, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31703/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31703/contributors\">",
"     Eric L Matteson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31703/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31703/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/61/31703/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural and synthetic glucocorticoids (also called steroids) can be used for a variety of disorders. These agents are most commonly given in pharmacologic doses to manage conditions that require the suppression of inflammation. Less often, they are used to establish the diagnosis and cause of Cushing's syndrome and for hormone replacement in adrenal insufficiency and congenital adrenal hyperplasia.",
"   </p>",
"   <p>",
"    The determinants of glucocorticoid dosing include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pharmacokinetics of the different drug preparations",
"     </li>",
"     <li>",
"      Effects of underlying disorders on drug kinetics",
"     </li>",
"     <li>",
"      Interactions of glucocorticoids with concurrently administered non-glucocorticoid drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the factors that affect glucocorticoid dosing. A detailed discussion of the structure, absorption, metabolism, and biologic activities of glucocorticoids is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOEQUIVALENCE AND BIOAVAILABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different preparations of glucocorticoids are largely bioequivalent (ie, have the same rate of absorption). As an example, most commercially available",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    tablets are bioequivalent, independent of tablet strength (eg, 1, 2, 5, 10, 20 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/1\">",
"     1",
"    </a>",
"    ], and the systemic bioavailability of prednisone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    are similar. Although the rectal and oral absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    are variable (relative bioavailability of 50 to 90 percent), such preparations are also bioequivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Glucocorticoid bioavailability does not appear to be affected by pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incomplete bioavailability of glucocorticoids has occasionally been noted in certain patients. As an example, in one study 20 percent of patients given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    showed poor bioavailability (23 to 65 percent), compared to only 1 of 12 patients given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dosing equivalents, relative antiinflammatory and mineralocorticoid activity, and duration of action of the different glucocorticoid preparations, shown in the table (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ), are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bioavailability of inhaled glucocorticoids varies with the physical properties of the particular agent. Eighty percent of inhaled glucocorticoids are swallowed, with the remainder deposited in the lungs. When deposited in the lungs, the more lipophilic compounds (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    ) are retained longer in lung tissue.",
"   </p>",
"   <p>",
"    The absorption of inhaled glucocorticoids also varies with the specific agents. Drugs that are highly lipophilic are relatively poorly absorbed orally (less than 11 percent). By comparison, agents which are not lipophilic (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ) are somewhat better absorbed orally (less than 20 percent). Since all of the drug deposited in the lung eventually enters the systemic circulation, overall absorption of inhaled glucocorticoids varies between 20 and 40 percent of the administered dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is rapidly metabolized via reduction to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ; the elimination of prednisone is approximately 13 times faster than prednisolone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast to cortisol, the endogenously produced glucocorticoid, the synthetic glucocorticoids bind less or minimally to cortisol-binding globulin (CBG, transcortin). Prednisolone has about 60 percent, prednisone 5 percent, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    have less than 1 percent of the affinity of cortisol for CBG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    is 210",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 with an elimination half-life of approximately three hours. Clearance decreases with age; as an example, children less than 12 years of age have a 33 percent higher clearance than older children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids exhibit dose-dependent kinetics. Total",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    clearance increases by 75 percent as the intravenous dose increases from 5 to 40 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Free prednisolone clearances also change with administered dose, but to a lesser degree and require larger doses to demonstrate such kinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/10\">",
"     10",
"    </a>",
"    ]. The clinical consequence of these properties is that a somewhat greater, nonlinear, drug effect is observed at prednisolone doses over 40 mg compared to doses between 10 to 20 mg.",
"   </p>",
"   <p>",
"    Clearances also vary with the time of day. Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    clearance is lower (18 to 28 percent) in the morning than the evening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This property, in combination with the disruption of the usual cortisol diurnal rhythm with exogenous glucocorticoids, may result in variations in efficacy when glucocorticoids are administered at different times during the day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one study, for example, the efficacy of prednisolone was assessed in seven asthmatic patients in whom the drug was given at 8 AM and 3 PM, and at 3 PM and 8 PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/15\">",
"     15",
"    </a>",
"    ]. The earlier dosing regimen was more effective in improving nocturnal pulmonary function and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Distribution in breast milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are excreted in small amounts in human milk. In one study, approximately 0.23 percent of a 5 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    dose was found in breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISEASES AND ALTERED PHYSIOLOGIC STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of glucocorticoids vary with certain diseases and pathophysiologic conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinically important pharmacokinetic differences between asthmatic patients and healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bioavailability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    appears to be unaffected by cystic fibrosis, but the total prednisolone clearance was increased by over 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/18\">",
"     18",
"    </a>",
"    ]. As a result, more frequent dosing may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients treated with hemodialysis, the clearance of total",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    is dose-dependent, while the clearance of unbound prednisolone is constant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/19\">",
"     19",
"    </a>",
"    ]. Hemodialysis also removes significant amounts of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , thereby resulting in a 32 percent reduction in plasma half-live relative to normals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/20\">",
"     20",
"    </a>",
"    ]. However, these changes are not sufficient to require a dose adjustment. The removal rate of unbound cortisol in patients treated with peritoneal dialysis is similar to normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    is increased in hyperthyroidism. In one small study, total prednisolone clearance was increased by 58 percent and nonrenal clearance (principally hepatic) was increased by 84 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/22\">",
"     22",
"    </a>",
"    ]. There were also small changes in absorption and binding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall kinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    do not appear to be affected by inflammatory bowel disease (IBD). One study, for example, found that total and unbound kinetics of prednisolone were unchanged in active and inactive IBD, although the unbound fraction was increased in active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients have low serum concentrations of albumin and cortisol-binding globulin. However, although their bound and therefore total glucocorticoid concentrations are reduced, the physiologically important unbound (free) serum concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    are similar to nonnephrotic individuals.",
"   </p>",
"   <p>",
"    Perhaps because of the differences in protein-binding, nonrenal clearance is higher and renal clearance is lower in patients with the nephrotic syndrome than in normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/24\">",
"     24",
"    </a>",
"    ]. The total",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    clearances are higher in nephrotic patients, since the increase in nonrenal clearance is of greater magnitude than the reduction in renal clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity can affect the uptake, storage, and metabolism of glucocorticoids, although results are somewhat contradictory.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the volume of distribution and clearance of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in obese men weighing more than 133 percent of ideal body weight was 20 to 30 percent higher than in normal weight controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, two other reports which examined the metabolism of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      found that clearance among obese patients was decreased by about 40 percent when compared to normals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. One of these studies also examined pharmacodynamic measures of glucocorticoid activity, particularly histamine and T cell responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/26\">",
"       26",
"      </a>",
"      ]. Although not statistically significant, there was a clear trend toward an enhanced effect in obese subjects at the same",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing of glucocorticoids in the obese patient should be based upon the ideal, rather than total, body weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little active",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    crosses the placenta to the fetus, since the placenta inactivates the drug. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    clearance is increased approximately twofold when compared to nonpregnant women, probably due to enzyme induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When an effect on the fetus is desired, for example to speed fetal lung maturity in situations where premature delivery is anticipated, fluorinated glucocorticoids are used because these cross the placenta and have pharmacologic effects on the fetal organs.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    are often used in this setting. Use of antenatal betamethasone is associated with a lower risk of neonatal death than is dexamethasone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Severe liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of severe liver disease, the activation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    via metabolism to 6-beta-hydroxyl compounds may be impaired, potentially affecting the efficacy of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who undergo liver transplantation because of hepatic C viral infection should receive the lowest dose of glucocorticoids following transplantation that is feasible. The cumulative glucocorticoid dose is correlated closely with post-transplantation hepatitis-C viral load and with mortality rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11170647\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids undergo metabolism in the liver and other tissues by cytochrome P450 3A4 (CYP 3A4) and other transformations. In vitro data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    are also substrates of P-glycoprotein membrane efflux transporters. &nbsp;Medications that strongly inhibit or induce CYP 3A4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    P-glycoprotein transporters may significantly alter the glucocorticoid serum concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications that increase the systemic glucocorticoid concentration include estrogen derivatives, such as oral contraceptives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/34-37\">",
"       34-37",
"      </a>",
"      ] and strong inhibitors of CYP 3A4 (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"       table 2",
"      </a>",
"      ) including some antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/16/41224?source=see_link\">",
"       telithromycin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/38-40\">",
"       38-40",
"      </a>",
"      ], and antifungals (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/33,41,42\">",
"       33,41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medications that reduce the systemic glucocorticoid concentration include",
"      <span class=\"nowrap\">",
"       aluminum/magnesium",
"      </span>",
"      containing antacids, which decrease",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      bioavailability due to decreased oral absorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/43,44\">",
"       43,44",
"      </a>",
"      ], and strong inducers of CYP 3A4 (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/45-50\">",
"       45-50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a number of agents often used with glucocorticoids appear to have no substantial interaction with them. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , histamine",
"    <sub>",
"     2",
"    </sub>",
"    antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    ), proton pump inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31703/abstract/45,51-55\">",
"     45,51-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major drug interactions with systemic glucocorticoids, a summary of effect(s), and management suggestions are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef53228 \" href=\"mobipreview.htm?16/58/17326\">",
"     table 3",
"    </a>",
"    ). &nbsp;For additional interactions, see Lexi-Interact&trade;, the drug interactions program included with UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11170962\">",
"    <span class=\"h2\">",
"     Inhaled or intranasal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of CYP 3A4 may impair the metabolism of glucocorticoids administered intranasally or by inhalation and may increase the serum concentration associated with these methods of administration. Use caution when combining high-dose intranasal or inhaled glucocorticoids with strong CYP 3A4 inhibitors (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 2",
"    </a>",
"    ). This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link&amp;anchor=H2446146#H2446146\">",
"     \"Pharmacotherapy of allergic rhinitis\", section on 'Possible drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link&amp;anchor=H26#H26\">",
"     \"Major side effects of inhaled glucocorticoids\", section on 'Medication interactions'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198637278\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The determinants of glucocorticoid dosing include pharmacokinetics of the different drug preparations, effects of underlying disorders on drug kinetics, and interactions of glucocorticoids with concurrently administered non-glucocorticoid drugs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The different preparations of glucocorticoids are largely bioequivalent (ie, have the same rate of absorption). The systemic bioavailability of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      are similar; the rectal and oral absorption of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      are variable (relative bioavailability of 50 to 90 percent). Incomplete bioavailability of glucocorticoids has occasionally been noted. The bioavailability of inhaled glucocorticoids varies with the physical properties of the particular agent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bioequivalence and bioavailability'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dosing equivalents, relative antiinflammatory and mineralocorticoid activity, and duration of action of the different glucocorticoid preparations, shown in the table (",
"      <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"       table 1",
"      </a>",
"      ), are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"       \"Pharmacologic use of glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      is rapidly metabolized via reduction to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      . In contrast to cortisol, the endogenously produced glucocorticoid, the synthetic glucocorticoids bind less or minimally to cortisol-binding globulin. Prednisolone has an elimination half-life of approximately three hours; clearance decreases with age and varies with time of day. Kinetics are dose-dependent. Only small amounts are excreted in breast milk. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Disposition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Clearance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Distribution in breast milk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pharmacokinetics of glucocorticoids vary with certain diseases and pathophysiologic conditions, including cystic fibrosis, end-stage renal disease and hemodialysis, hyperthyroidism, nephrotic syndrome, obesity, pregnancy, and severe liver disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diseases and altered physiologic states'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant interactions with glucocorticoids have been documented for the medications listed in the table (",
"      <a class=\"graphic graphic_table graphicRef53228 \" href=\"mobipreview.htm?16/58/17326\">",
"       table 3",
"      </a>",
"      ); a change of less than 30 percent is not likely to be clinically significant. Agents often used with glucocorticoids that appear to have no substantial interaction with them include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs that reduce the systemic glucocorticoid concentration include large doses of",
"      <span class=\"nowrap\">",
"       aluminum/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?31/6/31847?source=see_link\">",
"        magnesium hydroxide",
"       </a>",
"       ,",
"      </span>",
"      which decrease bioavailability, and most anticonvulsants, which enhance glucocorticoid metabolism. Drugs that raise the systemic glucocorticoid concentration include some oral contraceptives, and certain antibiotics and antifungal agents; these drugs decrease metabolizing enzymes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/1\">",
"      Francisco GE, Honigberg IL, Stewart JT, et al. In vitro and in vivo bioequivalence of commercial prednisone tablets. Biopharm Drug Dispos 1984; 5:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/2\">",
"      Lima JJ, Giller J, Mackichan JJ, Jusko WJ. Bioavailability of hydrocortisone retention enemas in normal subjects. Am J Gastroenterol 1980; 73:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/3\">",
"      Garg DC, Wagner JG, Sakmar E, et al. Rectal and oral absorption of methylprednisolone acetate. Clin Pharmacol Ther 1979; 26:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/4\">",
"      Elliott CL, Read GF, Wallace EM. The pharmacokinetics of oral and intramuscular administration of dexamethasone in late pregnancy. Acta Obstet Gynecol Scand 1996; 75:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/5\">",
"      Hill MR, Szefler SJ, Ball BD, et al. Monitoring glucocorticoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther 1990; 48:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/6\">",
"      Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/7\">",
"      Hale VG, Aizawa K, Sheiner LB, Benet LZ. Disposition of prednisone and prednisolone in the perfused rabbit liver: modeling hepatic metabolic processes. J Pharmacokinet Biopharm 1991; 19:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/8\">",
"      Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 1981; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/9\">",
"      Legler UF, Frey FJ, Benet LZ. Prednisolone clearance at steady state in man. J Clin Endocrinol Metab 1982; 55:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/10\">",
"      Wald JA, Law RM, Ludwig EA, et al. Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J Pharmacokinet Biopharm 1992; 20:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/11\">",
"      Meffin PJ, Wing LM, Sallustio BC, Brooks PM. Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br J Clin Pharmacol 1984; 17:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/12\">",
"      Fisher LE, Ludwig EA, Wald JA, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm. Clin Pharmacol Ther 1992; 51:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/13\">",
"      Sugita ET, Niebergall PJ. Bioavailability monograph: Prednisolone. J Am Pharm Assoc 1975; NS15:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/14\">",
"      Theissen JJ. Bioavailability monograph: Prednisolone. J Am Pharm Assoc 1976; NS16:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/15\">",
"      Reinberg A, Gervais P, Chaussade M, et al. Circadian changes in effectiveness of corticosteroids in eight patients with allergic asthma. J Allergy Clin Immunol 1983; 71:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/16\">",
"      Brooks PM, Needs CJ. The use of antirheumatic medication during pregnancy and in the puerperium. Rheum Dis Clin North Am 1989; 15:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/17\">",
"      Mortimer O, Grettve L, Lindstr&ouml;m B, et al. Bioavailability of prednisolone in asthmatic patients with a poor response to steroid treatment. Eur J Respir Dis 1987; 71:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/18\">",
"      Dove AM, Szefler SJ, Hill MR, et al. Altered prednisolone pharmacokinetics in patients with cystic fibrosis. J Pediatr 1992; 120:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/19\">",
"      Frey FJ, Gambertoglio JG, Frey BM, et al. Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Eur J Clin Pharmacol 1982; 23:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/20\">",
"      Sherlock JE, Letteri JM. Effect of hemodialysis on methylprednisolone plasma levels. Nephron 1977; 18:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/21\">",
"      Zager PG, Spalding CT, Frey HJ, et al. Dialysance of adrenocorticoids during continuous ambulatory peritoneal dialysis. J Clin Endocrinol Metab 1988; 67:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/22\">",
"      Frey FJ, Horber FF, Frey BM. Altered metabolism and decreased efficacy of prednisolone and prednisone in patients with hyperthyroidism. Clin Pharmacol Ther 1988; 44:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/23\">",
"      Milsap RL, George DE, Szefler SJ, et al. Effect of inflammatory bowel disease on absorption and disposition of prednisolone. Dig Dis Sci 1983; 28:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/24\">",
"      Frey FJ, Frey BM. Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. Am J Kidney Dis 1984; 3:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/25\">",
"      Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese men. Clin Pharmacol Ther 1984; 36:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/26\">",
"      Dunn TE, Ludwig EA, Slaughter RL, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991; 49:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/27\">",
"      Lamiable D, Vistelle R, Sulmont V, et al. [Pharmacokinetics of dexamethasone administered orally in obese patients]. Therapie 1990; 45:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/28\">",
"      Tsuei SE, Petersen MC, Ashley JJ, et al. Disporition of synthetic glucocorticoids. II. Dexamethasone in parturient women. Clin Pharmacol Ther 1980; 28:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/29\">",
"      Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol 2004; 190:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/30\">",
"      Renner E, Horber FF, Jost G, et al. Effect of liver function on the metabolism of prednisone and prednisolone in humans. Gastroenterology 1986; 90:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/31\">",
"      Charlton M. Management of recurrence of hepatitis C infection following liver transplantation. Minerva Chir 2003; 58:717.",
"     </a>",
"    </li>",
"    <li>",
"     Gary H. Wynn. Transplant surgery and rheumatology. In: Clinical manual of drug interaction principles for medical practice, 1st ed, Gary H. Wynn.  (Ed), APA Publishing Inc., Washington DC 2009. p.462.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/33\">",
"      Czock D, Keller F, Rasche FM, H&auml;ussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/34\">",
"      Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 1986; 40:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/35\">",
"      Boekenoogen SJ, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 1983; 56:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/36\">",
"      Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 1986; 62:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/37\">",
"      Frey BM, Schaad HJ, Frey FJ. Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. Eur J Clin Pharmacol 1984; 26:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/38\">",
"      LaForce CF, Szefler SJ, Miller MF, et al. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983; 72:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/39\">",
"      Szefler SJ, Brenner M, Jusko WJ, et al. Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clin Pharmacol Ther 1982; 32:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/40\">",
"      Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. J Allergy Clin Immunol 1982; 69:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/41\">",
"      Z&uuml;rcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989; 45:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/42\">",
"      Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther 1991; 49:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/43\">",
"      Tanner AR, Caffin JA, Halliday JW, Powell LW. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol 1979; 7:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/44\">",
"      Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology 1981; 80:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/45\">",
"      Stjernholm MR, Katz FH. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. J Clin Endocrinol Metab 1975; 41:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/46\">",
"      Frey FJ, Frey BM. Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. J Lab Clin Med 1983; 101:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/47\">",
"      Brooks SM, Werk EE, Ackerman SJ, et al. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972; 286:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/48\">",
"      Frey BM, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest 1984; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/49\">",
"      Evans PJ, Walker RF, Peters JR, et al. Anticonvulsant therapy and cortisol elimination. Br J Clin Pharmacol 1985; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/50\">",
"      Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 1977; 22:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/51\">",
"      Frey FJ, Lozada F, Guentert T, Frey BM. A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone. Eur J Clin Pharmacol 1981; 19:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/52\">",
"      Frey FJ, Schnetzer A, Horber FF, Frey BM. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. Transplantation 1987; 43:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/53\">",
"      Glynn-Barnhart AM, Erzurum SC, Leff JA, et al. Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. J Allergy Clin Immunol 1991; 88:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/54\">",
"      Sirgo MA, Rocci ML Jr, Ferguson RK, et al. Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Clin Pharmacol Ther 1985; 37:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31703/abstract/55\">",
"      Brooks SM, Sholiton LJ, Werk EE Jr, Altenau P. The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma. J Clin Pharmacol 1977; 17:308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7976 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31703=[""].join("\n");
var outline_f30_61_31703=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H198637278\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOEQUIVALENCE AND BIOAVAILABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Distribution in breast milk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISEASES AND ALTERED PHYSIOLOGIC STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Severe liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11170647\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11170962\">",
"      Inhaled or intranasal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H198637278\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7976|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/61/42972\" title=\"table 1\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 2\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/58/17326\" title=\"table 3\">",
"      Corticosteroid drug interact",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_61_31704="Eumycetoma";
var content_f30_61_31704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eumycetoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31704/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31704/contributors\">",
"     Beatriz Bustamante, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31704/contributors\">",
"     Pablo E Campos, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31704/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31704/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31704/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/61/31704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eumycetoma (\"mycotic mycetoma\") is a chronic subcutaneous fungal infection of the skin and soft tissue, most often affecting the lower extremity (typically a single foot). It is caused by more than 30 hyaline and pigmented species of molds. Filamentous higher bacteria can cause similar clinical manifestations (actinomycotic mycetoma or actinomycetoma); these organisms are discussed separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection typically occurs following skin or subcutaneous tissue inoculation of conidia via a contaminated thorn or splinter. Eumycetomas are usually confined to subcutaneous tissues but can involve fascia, bone, and regional lymph nodes via contiguous dissemination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment and prevention of eumycetoma will be reviewed here. Issues related to actinomycotic mycetoma caused by filamentous higher bacteria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29560?source=see_link\">",
"     \"Treatment of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of eumycetoma occur among individuals living in developing countries in tropical and subtropical regions, although cases have been reported worldwide (including in countries in temperate regions). Eumycetoma typically affects healthy adult men such as field laborers or farmers who work in rural areas and have frequent exposure to soil. The mean age is 33 but ranges from 8 to 68 years; pediatric cases are rare. The male to female ratio is about 3:1 to 5:1.",
"   </p>",
"   <p>",
"    Eumycetoma among animals is rare but has been reported in horses, water buffalo, and dogs. There are no known cases of zoonotic or laboratory acquisition of eumycetomas, nor has person to person transmission been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of eumycetoma infection is not fully understood. Risk factors appear to include environmental exposure to pathogenic organisms, genetic predisposition to infection, and immunosuppression.",
"   </p>",
"   <p>",
"    Eumycetoma begins with traumatic inoculation of the organism into cutaneous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subcutaneous tissues. Trauma may be minor (due to thorns, splinters, or other objects) and patients may not recall a specific injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, infection remains localized. Grains (colonies of infecting organisms) are deposited in infected tissues; free filaments do not develop. The grains are partially broken down via a neutrophil mediated inflammatory reaction; their remains perpetuate an inflammatory response. An epitheloid granuloma develops via recruitment of macrophages and multi-nucleated giant cells, which clear dead neutrophils and grain fragments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic predisposition to development of eumycetoma or actinomycetoma may be an important factor in pathogenesis. In endemic areas many individuals have antibodies to Madurella mycetomatis, the most common cause of eumycetoma, although only a small proportion of individuals develop disease. It has been postulated that some individuals lack sufficient neutrophil function to clear the organism, and, thus, they develop disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although eumycetoma frequently develops in the absence of immunosuppression, a number of cases have been reported in immunocompromised patients. These include one case due to Exophiala jeanselmei in a patient with an idiopathic CD4+ T-cell lymphocytopenia, and another case due by Madurella spp in a patient with acute myeloid leukemia undergoing chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Eumycetoma has also been described in solid organ transplant recipients; most had a good outcome with antifungal therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical management despite immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. One series described both eumycetoma and actinomycetoma in association with diabetes (9 out of 26 cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of the immune response in the setting of eumycetoma is not fully understood. One study described a reduction in cell-mediated immune response among patients with eumycetoma or actinomycetoma, but another failed to demonstrate any immune alteration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The small number of participants in these studies and the mixing of eumycetoma and actinomycetoma cases preclude drawing definitive conclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organisms capable of causing eumycetoma are distributed worldwide and include at least 30 hyaline and pigmented species of molds (",
"    <a class=\"graphic graphic_table graphicRef58060 \" href=\"mobipreview.htm?23/36/24141\">",
"     table 1",
"    </a>",
"    ). The predominant pathogen is Madurella mycetomatis, followed by Madurella grisea, Leptosphaeria senegalensis, and Pseudallescheria",
"    <span class=\"nowrap\">",
"     boydii/Scedosporium",
"    </span>",
"    apiospermum. Conventionally S. apiospermum has been considered the asexual state of P. boydii, but there is evidence that they might be two distinct species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/17\">",
"     17",
"    </a>",
"    ]. Because most reports do not differentiate between them, they are considered as one in this discussion and referred to as P. boydii. Additional eumycetoma agents are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef58060 \" href=\"mobipreview.htm?23/36/24141\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/18-24\">",
"     18-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. mycetomatis, M. grisea, P. boydii, and L. senegalensis are responsible for more than 90 percent of reported eumycetoma cases around the world (",
"    <a class=\"graphic graphic_figure graphicRef61250 \" href=\"mobipreview.htm?31/30/32224\">",
"     figure 1",
"    </a>",
"    ). In Africa, M. mycetomatis and L. senegalensis are the most common pathogens; M. grisea and P. boydii are less frequent pathogens. In South America, M. grisea is the most prevalent pathogen, followed by M. mycetomatis and P. boydii. In North America, P. boydii is the most prevalent pathogen, followed by M. grisea.",
"   </p>",
"   <p>",
"    The local prevalence of specific pathogens is determined by ecological conditions including temperature, rainfall, type of soil, prevalent vegetation, and pollution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/25\">",
"     25",
"    </a>",
"    ]. M. mycetomatis is common in arid zones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/26\">",
"     26",
"    </a>",
"    ], whereas P. boydii is common in temperate rainy areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/14,27\">",
"     14,27",
"    </a>",
"    ]. P. boydii is also found more frequently in nitrogen-rich environments with organic pollution from human, poultry and cattle manure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Soil is the natural reservoir for most of these agents. M. mycetomatis, M. grisea, P. boydii, Phialophora verrucosa, and N. rosatii have been isolated from soil samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. It has been demonstrated that thorns serve as mechanical vectors only after they are contaminated with soil. This was illustrated in an evaluation of thorns in the Senegal River region; culprit organisms were demonstrated on fallen Acacia thorns, but not on green thorns (eg, thorns not contaminated with soil) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causative agents of eumycetoma can be isolated in culture, demonstrating a stem consisting of septated filaments with mycelia. Grains (colonies of the pathogenic organism) may be seen in the discharge material from a draining sinus tract (microscopically",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    macroscopically) although in some cases they may be visible only by histopathological examination.",
"   </p>",
"   <p>",
"    Eumycetoma grains may be black or white to yellow (slightly creamy to yellow grains). Black grains are produced exclusively by fungi; M. mycetomatis is the most common cause of black grain eumycetoma. White to yellow grains may be produced by fungi causing eumycetoma or by bacteria causing actinomycetoma; P. boydii is the most common cause of white grain eumycetoma (",
"    <a class=\"graphic graphic_table graphicRef58060 \" href=\"mobipreview.htm?23/36/24141\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The grains of some species associated with eumycetoma have thickened fungal cell walls (including P. boydii, Fusarium spp, Acremonium killiense and M. mycetomatis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/33\">",
"     33",
"    </a>",
"    ]. Cell wall thickening may be an important factor in the difficulties associated with obtaining cultures from grains and targeting organisms with antifungal drugs. It may also represent a defense mechanism against phagocytic cells.",
"   </p>",
"   <p>",
"    Grain cement (composed in variable proportions by melanoproteins) strengthens the grain and protects cells from host antibodies, hydrolytic enzymes, and antifungal drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/34\">",
"     34",
"    </a>",
"    ]. The role of melanin is not fully understood, although it has been linked to virulence and pathogenicity. Melanization appears to protect the organism from strong oxidants and azole drugs in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eumycetoma is a chronic subcutaneous mycotic infection of the skin and soft tissue. Uncovered areas exposed to trauma are most commonly affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/36\">",
"     36",
"    </a>",
"    ]. The incubation period between inoculation and clinical manifestations is uncertain, and many patients may not recall a specific predisposing injury.",
"   </p>",
"   <p>",
"    Eumycetoma most frequently involves the feet, followed by legs and hands (80, 7 and 6 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/37\">",
"     37",
"    </a>",
"    ]. Workers who carry vegetable matter over exposed areas of the back or abdomen are susceptible to eumycetoma in these regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/38\">",
"     38",
"    </a>",
"    ]. Less frequent sites include buttocks, forearms, the groin area,",
"    <span class=\"nowrap\">",
"     head/neck,",
"    </span>",
"    perineum and testicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/3,14,37,39-42\">",
"     3,14,37,39-42",
"    </a>",
"    ]. The occurrence of multiple eumycetomas is rare and should prompt consideration of alternative diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic clinical triad includes tumor, sinus tracts, and macroscopic grains. Initially lesions are painless and commence as slowly growing indurated subcutaneous nodules (",
"    <a class=\"graphic graphic_picture graphicRef67717 \" href=\"mobipreview.htm?42/24/43393\">",
"     picture 1",
"    </a>",
"    ). Extension of lesions occurs due to nodular swelling and coalescence, forming large tumors that evolve into necrotic abscesses and draining sinus tracts (",
"    <a class=\"graphic graphic_picture graphicRef59276 \" href=\"mobipreview.htm?39/41/40596\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69384 \" href=\"mobipreview.htm?28/44/29376\">",
"     picture 3",
"    </a>",
"    ). These may produce serosanguineous or purulent discharge containing macroscopic or microscopic grains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"local\" href=\"#H5\">",
"     'Laboratory features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Eumycetoma may extend beyond the skin and subcutaneous tissues to adjacent structures including muscle, bone, and lymphatic vessels. Bone involvement is more frequent in the setting of chronic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/3,45\">",
"     3,45",
"    </a>",
"    ]. Lesions in areas with thin subcutaneous tissue (eg, feet, hands, and skull) are more likely to progress to bone involvement. Bone involvement indicates a poor prognosis and requires a longer course of therapy.",
"   </p>",
"   <p>",
"    Eumycetoma lesions may evolve over months, years or decades. In the absence of treatment they may become deforming and disabling tumors (",
"    <a class=\"graphic graphic_picture graphicRef54129 \" href=\"mobipreview.htm?33/23/34162\">",
"     picture 4",
"    </a>",
"    ). Other complications include fibrosis, ankylosis and lymphedema caused by lymphatic obstruction. The presence of pain is often associated with secondary bacterial infection (commonly caused by Staphylococcus aureus). In one series this was described as a complication of both eumycetoma and actinomycetoma in 66 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of eumycetoma is variable depending on the stage of the lesion, but actinomycetoma should always be ruled out. Early eumycetoma lesions can mimic foreign body granuloma, soft tissue tumors, cystic lesions, and folliculitis. In the absence of sinus tracts or grains, the differential diagnosis includes sporotrichosis, chromoblastomycosis, Basidiobolus or Candiobulus species infections, phaeohyphomycosis, hyalohyphomycosis, cutaneous leishmaniasis, tuberculosis, elephantiasis, and cellulitis. Bone involvement should prompt evaluation for bacterial osteomyelitis, tuberculosis and malignant bone tumors. (See related topics).",
"   </p>",
"   <p>",
"    In the setting of the characteristic clinical triad of tumor, sinus tracts, and macroscopic grains, eumycetoma may be presumed if actinomycetoma, botryomycosis, and actinomycosis have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the characteristic triad of tumor, sinus tracts, and macroscopic grains is useful for establishing a clinical diagnosis of eumycetoma, actinomycetoma, or actinomycosis. Black grains definitely indicate a fungal etiology, making a diagnosis of eumycetoma; while white to yellow grains may indicate fungal or bacterial infection. In the absence of sinus tracts or macroscopic grains, a deep abscess biopsy is needed to evaluate for presence of grains in the tissue. A fine needle aspiration smear is useful for diagnosis of eumycetoma if hyphae may be visualized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Grains should be examined by microscopy using 20 percent potassium hydroxide solution to identify fungal structures (broad, septate, and branching hyphae with large swollen cells at the edge) (",
"    <a class=\"graphic graphic_picture graphicRef67692 \" href=\"mobipreview.htm?32/3/32820\">",
"     picture 5",
"    </a>",
"    ). Gram staining may be used to demonstrate the presence of bacteria producing actinomycetoma or actinomycosis.",
"   </p>",
"   <p>",
"    Grains and tissue from deep biopsies must be cultured for species identification. Culture specimens should be washed with sterile saline solution prior to inoculation onto Sabouraud Dextrose Agar medium (with and without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    and cycloheximide). Inoculated plates must be kept at room temperature and at 37&ordm;C for 6 to 8 weeks because some causative agents grow relatively slowly. Following successful isolation in culture, standard mycological techniques may be used to for identification of the causative agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathological findings of eumycetoma consist of a chronic granulomatous reaction with purulent center. Grains of different morphologies may be observed; characteristics of grains inside the tissue may vary depending on the specific etiology (",
"    <a class=\"graphic graphic_picture graphicRef78858 \" href=\"mobipreview.htm?22/55/23412\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50368 \" href=\"mobipreview.htm?36/35/37431\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The histopathology evaluation should include hematoxylin andeosin as well as periodic acid-Schiff (PAS) or Gomori",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver staining. Fungal structures (broad, septate, and branching hyphae with large swollen cells at the edge) may be seen; hyphae may be hyaline or pigmented. Grain cement may or may not be seen; if present it may be compact or loose. These characteristics are useful for presumptive species identification but may not be used for definitive diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The characteristic histopathology of Madurella mycetomatis consists of large grains with intertwining hyphae embedded in interstitial brownish cement and numerous swollen cells at the periphery.",
"     </li>",
"     <li>",
"      The characteristic histopathology of Pseudallescheria boydii consists of eosinophilic grains with a clearer central area, abundant swollen cells, and without cement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific fluorescent antibody reagents have been developed to detect and identify P. boydii in tissues, providing a rapid and reliable method for diagnosing the infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, monoclonal antibodies against Aspergillus galactomannan have shown high sensitivity and specificity in identifying Aspergillus species in formalin-fixed tissues without cross-reactivity with other filamentous fungi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic imaging is useful for determining the extent of disease, including soft tissue and bone involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/51\">",
"     51",
"    </a>",
"    ]. Findings in the setting of both eumycetoma and actinomycetoma include soft tissue swelling, osteoporosis and osteolytic lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69857 \" href=\"mobipreview.htm?42/7/43135\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cavities in eumycetoma lesions tend to be few in number and &ge;1 cm in diameter, with well-defined margins; they are frequently filled with grains. In contrast, cavitary lesions due to bacterial pathogens tend to be smaller but more numerous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/25,55\">",
"     25,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography (CT) is more sensitive than conventional radiographs for assessing early bone involvement, although it is not as sensitive as magnetic resonance imaging (MRI).",
"   </p>",
"   <p>",
"    MRI demonstrating a \"dot-in-circle sign\" correlates with inflammatory granulomata containing grains and surrounded by fibrous matrix (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77021 \" href=\"mobipreview.htm?7/48/7940\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/56\">",
"     56",
"    </a>",
"    ]. This has been proposed as a specific sign of both eumycetoma and actinomycetoma (regardless of the etiological agent). MRI is also useful for determining the extent of soft tissue involvement, as well as for following signs of response to treatment including reduction in the volume of inflammatory tissue, transformation of inflammatory changes into fibrotic tissue and reduction of bone destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/51,57\">",
"     51,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serology and molecular testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standardized serological test for diagnosis of eumycetoma. In circumstances when macroscopic and microscopic features of the isolate are not sufficient for precise identification (due to absence of spores or other distinctive structures), molecular techniques may be useful. The internal transcribed spacer region of ribosomal DNA sequencing allows the identification of different fungal species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/18,58-60\">",
"     18,58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of eumycetoma consists of prolonged drug therapy. The role of surgery is limited; if pursued, surgery should always be performed in conjunction with antifungal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective randomized clinical trials to determine the most effective drug therapy for eumycetoma. Published reports mix both eumycetoma and actinomycetoma cases and do not differentiate between those with and without bone involvement. Therefore, the approach to management is based on few case reports with small numbers of patients with limited follow up periods.",
"   </p>",
"   <p>",
"    The causative agent should be identified prior to initiation of therapy if feasible. In vitro susceptibility testing need not be performed routinely. Selection and duration of therapy must be tailored depending on individual patient circumstances, as in vitro susceptibility testing does not always predict the clinical response to therapy.",
"   </p>",
"   <p>",
"    Antifungal therapy for eumycetoma should consist of azole antifungals;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has not proven effective for long-term cure. The most useful agents appear to be",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is not adequate therapy for treatment of eumycetoma because of intrinsic resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The earliest studies of azoles for treatment of eumycetoma were performed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/14,62-64\">",
"     14,62-64",
"    </a>",
"    ]. In one study of 50 patients with M. mycetomatis, treatment with ketoconazole (200 mg twice daily) led to improvement or cure in 72 percent of cases (duration of therapy 9 to 36 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/62\">",
"     62",
"    </a>",
"    ]. In general, likelihood for cure has appeared relatively favorable with ketoconazole treatment for &ge;6 months, but adverse drug events limit the long term use of this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/14,63\">",
"     14,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports have reported mixed success with use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , although this agent is better tolerated than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/14,62,65,66\">",
"     14,62,65,66",
"    </a>",
"    ]. Among a small number of patients with M. mycetomatis, Itraconazole (100 mg twice daily) led to improvement in 42 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/14\">",
"     14",
"    </a>",
"    ]. Itraconazole drug level monitoring should be undertaken (if feasible), since absorption of itraconazole may be erratic. Monitoring should be performed after the steady state has been reached in about two weeks, and the goal is to maintain the itraconazole serum level above 1",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    In cases of intolerance or refractoriness to itraconazole, acceptable alternatives include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (dosing outlined below) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    (200 mg orally four times daily or 400 mg twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is the preferred agent for treatment of eumycetoma due to P. boydii, since this species has demonstrated resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/68-74\">",
"     68-74",
"    </a>",
"    ]. Voriconazole has been used for treatment of invasive infections due to P. boydii with good results, including severe forms or disseminated disease involving central nervous system and bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/75-82\">",
"     75-82",
"    </a>",
"    ]. Voriconazole therapy consists of a loading dose 400 mg orally every 12 hours for the first 24 hours, followed by 200 mg twice daily; the dose may be increased to 300 mg twice daily if needed.",
"   </p>",
"   <p>",
"    There are no standardized criteria for clinical evaluation and follow up of eumycetoma. Treatment must be administered for prolonged periods, long after clinical and radiologic signs of disease have disappeared. Hepatic enzyme monitoring must be performed monthly in the setting of azole therapy. Cure may be established only after at least two years of follow-up after the end of treatment. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of eumycetoma due to M. mycetomatis, M. grisea or L. senegalensis we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , given its greater tolerability over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    . For treatment of eumycetoma due to P. boydii, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    . Dosing for these agents is as outlined in the previous section.",
"   </p>",
"   <p>",
"    Therapeutic alternatives depend on the species:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      M. mycetomatis and M. grisea &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (200 mg orally four times daily or 400 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      (400 to 800 mg orally daily)",
"     </li>",
"     <li>",
"      L. senegalensis &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"     </li>",
"     <li>",
"      P. boydii &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For eumycetoma caused by Exophiala, Acremonium, Fusarium or Aspergillus species, the preferred therapy is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (100 to 200 mg orally twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery for management of eumycetoma is limited, since relapse rates after surgery are high (over 50 percent). If surgery is deemed warranted, it always should be performed in conjunction with administration of antifungal therapy prior to and following debridement. The use of antifungal drugs before surgery reduces the size of the tumor, and their use after surgery reduces the recurrence rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. At least six months of antifungal therapy should be administered prior to consideration of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery should be considered early in cases of small and well-demarcated lesions only, and a wide margin of healthy tissue must be excised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/86\">",
"     86",
"    </a>",
"    ]. There is no utility for radical surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/55\">",
"     55",
"    </a>",
"    ]. Surgery is not warranted to remove grains or reduce pain and swelling caused by draining sinuses. Amputation may be considered only for those cases with severe, progressive disability; if needed, the goal of amputation should be to prevent further deterioration in quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy for eumycetoma is uncertain and depends on individual circumstances. In general, at least 12 months of therapy is appropriate, but treatment may be required for two years or more. Bone involvement indicates a poor prognosis and requires a longer course of therapy. Treatment should be continued for at least three months after a clinic and radiologic cure is achieved. Hepatic enzyme monitoring must be performed monthly during azole therapy.",
"   </p>",
"   <p>",
"    Clinical and radiographic follow-up are needed to determine response to therapy. Clinical signs of improvement include reduction in swelling, decreasing purulent discharge, closing of sinus tracts, reduction in pain and improvement of mobility. Radiographic signs of improvement include resolution of signs indicative of active osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repeat cultures or biopsies are not useful. Biopsy findings may demonstrate fibrosis replacing the former granulomatous reaction, but the sensitivity for identifying grains in tissue samples is low when fistulae are closed.",
"   </p>",
"   <p>",
"    Eumycetoma patients should be followed for at least two years after end of treatment before declaring a cure. There is no consensus on the precise definition of eumycetoma cure; some define cured after two years free of active disease, while others require longer periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31704/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of protective equipment including shoes and gloves should be promoted in the setting of contact with soil whenever possible. In addition, healthcare professionals working in endemic areas must be educated to recognize and treat eumycetoma promptly before progression to advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eumycetoma is a chronic subcutaneous fungal infection of the skin and soft tissue, most often affecting the lower extremity. It is caused by more than 30 species of molds.(See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of eumycetoma occur among individuals living in developing countries in tropical and subtropical regions, although cases have been reported worldwide. Eumycetoma most frequently involves the feet, followed by legs and hands, where exposure to contaminated soil occurs most commonly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eumycetoma begins with traumatic inoculation of the organism into cutaneous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subcutaneous tissues. Trauma may be minor (due to thorns, splinters, or other objects) and patients may not recall a specific injury. Grains (which are actual colonies of infecting organisms) are deposited in infected tissues and partially broken down via a neutrophil mediated inflammatory reaction. Their remains perpetuate an inflammatory response. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organisms capable of causing eumycetoma are distributed worldwide and include at least 30 hyaline and pigmented species of molds (",
"      <a class=\"graphic graphic_table graphicRef58060 \" href=\"mobipreview.htm?23/36/24141\">",
"       table 1",
"      </a>",
"      ). The predominant pathogen is Madurella mycetomatis, followed by Madurella grisea, Leptosphaeria senegalensis, and Pseudallescheria",
"      <span class=\"nowrap\">",
"       boydii/Scedosporium",
"      </span>",
"      apiospermum. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microbiology evaluation includes microscopic examination as well as culture of grains and deep biopsy specimens. Grains may be seen in the discharged material from a draining sinus tract (microscopically",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      macroscopically) although in some cases they may be visible only by histopathological examination. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of the characteristic triad of tumor, sinus tracts, and macroscopic grains is useful for establishing a clinical diagnosis of eumycetoma, actinomycetoma or actinomycosis. Black grains definitely indicate a fungal etiology, establishing a diagnosis of eumycetoma, while white to yellow grains may indicate fungal or bacterial infection. In the absence of sinus tracts or macroscopic grains, a deep abscess biopsy is needed to evaluate for presence of grains in the tissue. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of eumycetoma due to M. mycetomatis, M. grisea or L. senegalensis we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , given its greater tolerability over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For treatment of eumycetoma due to P. boydii, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of therapy for eumycetoma is uncertain and depends on individual circumstances. In general, at least 12 months of therapy is appropriate, but treatment may be required for two years or more. Eumycetoma patients should be followed for at least two years after end of treatment before declaring a cure. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of surgery for management of eumycetoma is limited, since relapse rates after surgery are over 50 percent. &nbsp;If surgery is deemed warranted, it always should be performed in conjunction with administration of antifungal therapy prior to and following debridement. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/1\">",
"      Ameen M, Arenas R. Developments in the management of mycetomas. Clin Exp Dermatol 2009; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/2\">",
"      el Hassan AM, Mahgoub ES. Lymph node involvement in mycetoma. Trans R Soc Trop Med Hyg 1972; 66:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/3\">",
"      ABBOTT P. Mycetoma in the Sudan. Trans R Soc Trop Med Hyg 1956; 50:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/4\">",
"      Yu AM, Zhao S, Nie LY. Mycetomas in northern Yemen: identification of causative organisms and epidemiologic considerations. Am J Trop Med Hyg 1993; 48:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/5\">",
"      Lee MW, Kim JC, Choi JS, et al. Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole. J Am Acad Dermatol 1995; 32:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/6\">",
"      Fahal AH, el Toum EA, el Hassan AM, et al. The host tissue reaction to Madurella mycetomatis: new classification. J Med Vet Mycol 1995; 33:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/7\">",
"      van de Sande WW, Fahal A, Verbrugh H, van Belkum A. Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immunol 2007; 179:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/8\">",
"      Neumeister B, Zollner TM, Krieger D, et al. Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses 1995; 38:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/9\">",
"      Satta R, Sanna S, Cottoni F. Madurella infection in an immunocompromised host. Int J Dermatol 2000; 39:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/10\">",
"      Geyer AS, Fox LP, Husain S, et al. Acremonium mycetoma in a heart transplant recipient. J Am Acad Dermatol 2006; 55:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/11\">",
"      Meis JF, Schouten RA, Verweij PE, et al. Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient. Transpl Infect Dis 2000; 2:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/12\">",
"      O'Riordan E, Denton J, Taylor PM, et al. Madura foot in the U.K.: fungal osteomyelitis after renal transplantation. Transplantation 2002; 73:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/13\">",
"      Van Etta LL, Peterson LR, Gerding DN. Acremonium falciforme (Cephalosporium falciforme) mycetoma in a renal transplant patient. Arch Dermatol 1983; 119:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/14\">",
"      Hay RJ, Mahgoub ES, Leon G, et al. Mycetoma. J Med Vet Mycol 1992; 30 Suppl 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/15\">",
"      Mahgoub ES, Gumaa SA, El Hassan AM. Immunological status of mycetoma patients. Bull Soc Pathol Exot Filiales 1977; 70:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/16\">",
"      Bendl BJ, Mackey D, Al-Saati F, et al. Mycetoma in Saudi Arabia. J Trop Med Hyg 1987; 90:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/17\">",
"      Gilgado F, Cano J, Gen&eacute; J, et al. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol 2008; 46:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/18\">",
"      Hemashettar BM, Siddaramappa B, Munjunathaswamy BS, et al. Phaeoacremonium krajdenii, a cause of white grain eumycetoma. J Clin Microbiol 2006; 44:4619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/19\">",
"      Aguilar-Donis A, Torres-Guerrero E, Arenas-Guzm&aacute;n R, et al. Mycetoma caused by Phaeoacremonium parasiticum--a case confirmed with B-tubulin sequence analysis. Mycoses 2011; 54:e615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/20\">",
"      de Hoog GS, van Diepeningen AD, Mahgoub el-S, van de Sande WW. New species of Madurella, causative agents of black-grain mycetoma. J Clin Microbiol 2012; 50:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/21\">",
"      Hashemi SJ, Nasrollahi A, Guerami M, et al. Mycetoma in Iran: study of 62 cases. Asian J Epidemiol 2008; 1:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/22\">",
"      Iriart X, Binois R, Fior A, et al. Eumycetoma caused by Diaporthe phaseolorum (Phomopsis phaseoli): a case report and a mini-review of Diaporthe/Phomopsis spp invasive infections in humans. Clin Microbiol Infect 2011; 17:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/23\">",
"      Mhmoud NA, Ahmed SA, Fahal AH, et al. Pleurostomophora ochracea, a novel agent of human eumycetoma with yellow grains. J Clin Microbiol 2012; 50:2987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/24\">",
"      Motswaledi HM, Mathekga K, Sein PP, Nemutavhanani DL. Paecilomyces lilacinus eumycetoma. Int J Dermatol 2009; 48:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/25\">",
"      Boiron P, Locci R, Goodfellow M, et al. Nocardia, nocardiosis and mycetoma. Med Mycol 1998; 36 Suppl 1:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/26\">",
"      MARIAT F. [On the geographic distribution and incidence of mycetoma agents]. Bull Soc Pathol Exot Filiales 1963; 56:35.",
"     </a>",
"    </li>",
"    <li>",
"     Mahgoub ES. Mycetoma. In: Tropical Mycoses, Mahgoub ES (Ed), Jansen Research Council, 1989. p.57.",
"    </li>",
"    <li>",
"     Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes, 2nd, WB Saunders Co, Philadelphia 1982. p.596.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/29\">",
"      Gezuele E, Mackinnon JE, Conti-D&iacute;az IA. The frequent isolation of Phialophora verrucosa and Phialophora pedrosoi from natural sources. Sabouraudia 1972; 10:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/30\">",
"      Ahmed A, Adelmann D, Fahal A, et al. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan. J Clin Microbiol 2002; 40:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/31\">",
"      Segretain G, Mariat F. [Research on the presence of agents of mycetoma in the soil and thorny plants of Senegal and Mauritania]. Bull Soc Pathol Exot Filiales 1968; 61:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/32\">",
"      Segretain G. [Epidemiology of mycetomas]. Ann Soc Belg Med Trop 1972; 52:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/33\">",
"      Hay RJ, Collins MJ. An ultrastructural study of pale eumycetoma grains. Sabouraudia 1983; 21:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/34\">",
"      Findlay GH, Vismer HF. Black grain mycetoma. A study of the chemistry, formation and significance of the tissue grain in Madurella mycetomi infection. Br J Dermatol 1974; 91:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/35\">",
"      van de Sande WW, de Kat J, Coppens J, et al. Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect 2007; 9:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/36\">",
"      Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health 2002; 7:788.",
"     </a>",
"    </li>",
"    <li>",
"     Bustamante B, Campos PE. Eumycetoma. In: Kauffman CA, 2nd, Atlas of fungal infections (Ed), Current Medicine LLC, 2007. p.203.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/38\">",
"      L&oacute;pez Mart&iacute;nez R, M&eacute;ndez Tovar LJ, Lavalle P, et al. [Epidemiology of mycetoma in Mexico: study of 2105 cases]. Gac Med Mex 1992; 128:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/39\">",
"      Soni N, Gupta A, Shekhawat NS. Mycetoma - an unusual site. Surgery 2000; 127:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/40\">",
"      Ly F, Develoux M, Deme A, et al. [Tumoral mycetoma of the buttock]. Ann Dermatol Venereol 2000; 127:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/41\">",
"      Gumaa SA, Satir AA, Shehata AH, Mahgoub ES. Tumor of the mandible caused by Madurella mycetomil. Am J Trop Med Hyg 1975; 24:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/42\">",
"      Arbab MA, el Hag IA, Abdul Gadir AF. Intraspinal mycetoma: report of two cases. Am J Trop Med Hyg 1997; 56:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/43\">",
"      Fahal AH, el Hassan AM, Abdelalla AO, Sheik HE. Cystic mycetoma: an unusual clinical presentation of Madurella mycetomatis infection. Trans R Soc Trop Med Hyg 1998; 92:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/44\">",
"      Hazra B, Bandyopadhyay S, Saha SK, et al. A study of mycetoma in eastern India. J Commun Dis 1998; 30:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/45\">",
"      Castro LG, Belda J&uacute;nior W, Salebian A, Cuc&eacute; LC. Mycetoma: a retrospective study of 41 cases seen in S&atilde;o Paulo, Brazil, from 1978 to 1989. Mycoses 1993; 36:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/46\">",
"      Ahmed AO, Abugroun ES. Unexpected high prevalence of secondary bacterial infection in patients with mycetoma. J Clin Microbiol 1998; 36:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/47\">",
"      Gabhane SK, Gangane N. Cytodiagnosis of eumycotic mycetoma: a case report. Acta Cytol 2008; 52:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/48\">",
"      Jackson JA, Kaplan W, Kaufman L, Standard P. Development of fluorescent-antibody reagents for demonstration of Pseudallescheria boydii in tissues. J Clin Microbiol 1983; 18:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/49\">",
"      Choi JK, Mauger J, McGowan KL. Immunohistochemical detection of Aspergillus species in pediatric tissue samples. Am J Clin Pathol 2004; 121:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/50\">",
"      Fenelon LE, Hamilton AJ, Figueroa JI, et al. Production of specific monoclonal antibodies to Aspergillus species and their use in immunohistochemical identification of aspergillosis. J Clin Microbiol 1999; 37:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/51\">",
"      Czechowski J, Nork M, Haas D, et al. MR and other imaging methods in the investigation of mycetomas. Acta Radiol 2001; 42:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/52\">",
"      Al-Ali AA, Kashgari TQ, Nathani PG, Moawad MK. Radiological manifestations of madura foot in the Eastern Province of Saudi Arabia. Ann Saudi Med 1997; 17:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/53\">",
"      Abd Bagi ME, Fahal AH, Sheik HE, et al. Pathological fractures in mycetoma. Trans R Soc Trop Med Hyg 2003; 97:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/54\">",
"      Tomimori-Yamashita J, Ogawa MM, Hirata SH, et al. Mycetoma caused by Fusarium solani with osteolytic lesions on the hand: case report. Mycopathologia 2002; 153:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/55\">",
"      McGinnis MR. Mycetoma. Dermatol Clin 1996; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/56\">",
"      Sarris I, Berendt AR, Athanasous N, et al. MRI of mycetoma of the foot: two cases demonstrating the dot-in-circle sign. Skeletal Radiol 2003; 32:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/57\">",
"      Sharif HS, Clark DC, Aabed MY, et al. Mycetoma: comparison of MR imaging with CT. Radiology 1991; 178:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/58\">",
"      Ahmed A, van de Sande W, Verbrugh H, et al. Madurella mycetomatis strains from mycetoma lesions in Sudanese patients are clonal. J Clin Microbiol 2003; 41:4537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/59\">",
"      Loulergue P, Hot A, Dannaoui E, et al. Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg 2006; 75:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/60\">",
"      Desnos-Ollivier M, Bretagne S, Dromer F, et al. Molecular identification of black-grain mycetoma agents. J Clin Microbiol 2006; 44:3517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/61\">",
"      Salkin IF, McGinnis MR, Dykstra MJ, Rinaldi MG. Scedosporium inflatum, an emerging pathogen. J Clin Microbiol 1988; 26:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/62\">",
"      Welsh O, Salinas MC, Rodr&iacute;guez MA. Treatment of eumycetoma and actinomycetoma. Curr Top Med Mycol 1995; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/63\">",
"      Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg 1984; 78:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/64\">",
"      Venugopal PV, Venugopal TV, Ramakrishna ES, Ilavarasi S. Antimycotic susceptibility testing of agents of black grain eumycetoma. J Med Vet Mycol 1993; 31:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/65\">",
"      Resnik BI, Burdick AE. Improvement of eumycetoma with itraconazole. J Am Acad Dermatol 1995; 33:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/66\">",
"      Smith EL, Kutbi S. Improvement of eumycetoma with itraconazole. J Am Acad Dermatol 1997; 36:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/67\">",
"      N'diaye B, Dieng MT, Perez A, et al. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol 2006; 45:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/68\">",
"      Cuenca-Estrella M, Ruiz-D&iacute;ez B, Mart&iacute;nez-Su&aacute;rez JV, et al. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999; 43:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/69\">",
"      Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/70\">",
"      Zeng J, Kamei K, Zheng Y, Nishimura K. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents. Nihon Ishinkin Gakkai Zasshi 2004; 45:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/71\">",
"      Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/72\">",
"      Meletiadis J, Mouton JW, Rodriguez-Tudela JL, et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000; 44:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/73\">",
"      Walsh TJ, Peter J, McGough DA, et al. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 1995; 39:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/74\">",
"      Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997; 41:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/75\">",
"      McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol 1998; 36:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/76\">",
"      Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000; 31:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/77\">",
"      Mu&ntilde;oz P, Mar&iacute;n M, Tornero P, et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/78\">",
"      Porte L, Khatibi S, Hajj LE, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg 2006; 100:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/79\">",
"      Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/80\">",
"      Lexier R, Walmsley SL. Successful treatment of Madura foot caused by Pseudallescheria boydii with Escherichia coli superinfection: a case report. Can J Surg 1999; 42:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/81\">",
"      Turner PG. Madura foot or plantar fibromatosis. J Bone Joint Surg Br 1989; 71:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/82\">",
"      Schaenman JM, DiGiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 2005; 43:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/83\">",
"      Fothergill AW, Rinaldi MG, Sutton DA. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Med Mycol 2009; 47:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/84\">",
"      Welsh O. Mycetoma. Current concepts in treatment. Int J Dermatol 1991; 30:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31704/abstract/85\">",
"      Mahgoub, ES. Mycetoma. Semin Dermatol 1985; 4:230.",
"     </a>",
"    </li>",
"    <li>",
"     Kwon-Chung KJ, Bennett JE. Mycetoma. In: Medical Mycology, Lea &amp; Febiger, Philadelphia 1992. p.560.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2439 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-2522EA1FE6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31704=[""].join("\n");
var outline_f30_61_31704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serology and molecular testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2439\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2439|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/7/43135\" title=\"diagnostic image 1\">",
"      Eumycetoma with cavities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/48/7940\" title=\"diagnostic image 2\">",
"      Eumycetoma after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2439|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/30/32224\" title=\"figure 1\">",
"      Relative incidence eumycetoma organisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2439|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/24/43393\" title=\"picture 1\">",
"      Small mycetoma lesion A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/41/40596\" title=\"picture 2\">",
"      Small mycetoma lesion B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/44/29376\" title=\"picture 3\">",
"      Eumycetoma foot A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/23/34162\" title=\"picture 4\">",
"      Eumycetoma foot B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/3/32820\" title=\"picture 5\">",
"      Black grain direct exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/55/23412\" title=\"picture 6\">",
"      Black grain histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/35/37431\" title=\"picture 7\">",
"      M mycetomatis skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2439|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/36/24141\" title=\"table 1\">",
"      Organisms that cause eumycetoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29560?source=related_link\">",
"      Treatment of nocardiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_61_31705="Peritonsillar cellulitis and abscess";
var content_f30_61_31705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peritonsillar cellulitis and abscess",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     Ellen R Wald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/61/31705/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/61/31705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppurative infections of the neck are uncommon. However, they are potentially very serious. Suppurative cervical lymphadenitis is the most common superficial neck infection. Peritonsillar abscess (PTA, quinsy) is the most common deep neck infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Other deep neck infections include retropharyngeal abscess and parapharyngeal space abscess (also known as pharyngomaxillary or lateral pharyngeal space abscess). Pharyngeal space infection most often arises via contiguous spread of infection from a peritonsillar or retropharyngeal abscess.",
"   </p>",
"   <p>",
"    The clinical features, evaluation, and management of peritonsillar cellulitis (also called peritonsillitis) and abscess will be discussed here. Cervical lymphadenitis, retropharyngeal cellulitis and abscess, and other deep neck space infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8632?source=see_link\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2591682\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two terms are used to describe infection of the peritonsillar region:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritonsillar cellulitis &ndash; Peritonsillar cellulitis is an inflammatory reaction of the tissue between the capsule of the palatine tonsil and the pharyngeal muscles that is caused by infection, but not associated with a discrete collection of pus. An alternate term for cellulitis is phlegmon.",
"     </li>",
"     <li>",
"      Peritonsillar abscess &ndash; Peritonsillar abscess is a collection of pus located between the capsule of the palatine tonsil and the pharyngeal muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In many patients, diagnosing the type of peritonsillar infection present requires needle aspiration or incision and drainage to determine if pus is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peritonsillar space consists of loose areolar tissue overlying the tonsil and is surrounded by the superior pharyngeal constrictor muscle and the anterior and posterior tonsillar pillars. The palatine tonsils are located between the palatoglossal and palatopharyngeal arches (",
"    <a class=\"graphic graphic_figure graphicRef72358 \" href=\"mobipreview.htm?41/4/42053\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/3\">",
"     3",
"    </a>",
"    ]. They are surrounded by a capsule that provides a path for blood vessels and nerves.",
"   </p>",
"   <p>",
"    PTA usually occurs in the superior pole of the tonsil, manifest by a defined collection of pus between the tonsillar capsule, the superior constrictor, and the palatopharyngeus muscle. PTA also may occur in the midpoint or inferior pole of the tonsil, or may be dispersed with multiple loculations in the peritonsillar space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritonsillar infection generally is preceded by tonsillitis or pharyngitis and progresses from cellulitis to phlegmon to abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/4\">",
"     4",
"    </a>",
"    ]. PTA also may occur without preceding infection; such cases are thought to be caused by obstruction of the Weber glands (a group of salivary glands in the soft palate just superior to the tonsil and connected to the surface of the tonsil by a duct) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Smoking appears to be a risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritonsillar infection may compromise the upper airway or spread to the surrounding structures, including the masseter and pterygoid muscles and the carotid sheath (",
"    <a class=\"graphic graphic_figure graphicRef67251 \" href=\"mobipreview.htm?7/39/7797\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonsillar abscess (PTA) is the most common deep neck infection in children and adolescents, accounting for at least 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It occurs most frequently in adolescents and young adults, but can also occur in younger children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated annual incidence of PTA is 30 per 100,000 persons 5 to 59 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/11\">",
"     11",
"    </a>",
"    ]. In a population-based review, the overall incidence of suspected PTA, based upon clinical suspicion in children &lt;18 years was 14 per 100,000; the incidence in adolescents was 40 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/12\">",
"     12",
"    </a>",
"    ]. The incidence of confirmed PTA by the presence of pus with drainage procedures was 3 per 100,000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonsillar abscesses are often polymicrobial. The predominant bacterial species are Streptococcus pyogenes (group A streptococcus [GAS]), Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), and respiratory anaerobes (including Fusobacteria, Prevotella, and Veillonella species) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Haemophilus species are found occasionally. If appropriate microbiologic techniques are used, it is not uncommon for aerobes and anaerobes to be recovered simultaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in the evaluation of the patient with potential deep neck space infection is rapid assessment of the degree of upper airway obstruction. Anxious, ill-appearing patients with drooling and posturing must be monitored continuously in a setting where emergent artificial airway can be established if necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link&amp;anchor=H22#H22\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Initial rapid assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical clinical presentation of peritonsillar abscess (PTA) is a severe sore throat (usually unilateral), fever, and a \"hot potato\" or muffled voice. Pooling of saliva or drooling may be present. Trismus, related to irritation and reflex spasm of the internal pterygoid muscle, occurs in nearly two-thirds of patients; it helps to distinguish PTA from severe pharyngitis or tonsillitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. Patients often have neck swelling and pain and may have ipsilateral ear pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/3\">",
"     3",
"    </a>",
"    ]. Fatigue, irritability, and decreased oral intake may occur as a result of discomfort.",
"   </p>",
"   <p>",
"    Historical features are important in guiding management. Important aspects of the history include frequency and severity of recurrent episodes of infectious pharyngitis, previous episodes of peritonsillar abscess, and snoring or other symptoms of obstructive sleep apnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=see_link\">",
"     \"Tonsillectomy and adenoidectomy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of trismus may limit the ability to perform an adequate examination. If drooling is present, suggesting the possibility of epiglottitis, care must be taken not to be aggressive during the examination of the oral cavity. If there is doubt about whether the patient has a peritonsillar abscess (PTA), epiglottitis, or other deep neck space infection, imaging or examination in the operating room may be necessary. Examination in the operating room permits controlled placement of an artificial airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Imaging'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination findings consistent with PTA include an extremely swollen and fluctuant tonsil with deviation of the uvula to the opposite side (",
"    <a class=\"graphic graphic_picture graphicRef69943 \" href=\"mobipreview.htm?29/54/30575\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/4,5,18\">",
"     4,5,18",
"    </a>",
"    ]. Alternatively, there may be fullness or bulging of the posterior soft palate near the tonsil with palpable fluctuance. Findings in children with peritonsillar cellulitis may include an erythematous pharynx and enlarged tonsils with exudate (",
"    <a class=\"graphic graphic_picture graphicRef58619 \" href=\"mobipreview.htm?40/34/41509\">",
"     picture 2",
"    </a>",
"    ); uvular deviation and trismus are usually absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/17\">",
"     17",
"    </a>",
"    ]. Cervical and submandibular lymphadenopathy may be present in children with PTA or cellulitis.",
"   </p>",
"   <p>",
"    Bilateral PTA is rare. Clinical diagnosis may be difficult because the classic asymmetric findings are absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Symptoms, such as odynophagia and trismus, may suggest the diagnosis, but are not always present. The uvula may be displaced anteriorly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/23\">",
"     23",
"    </a>",
"    ]. Bilateral PTA may be complicated by upper airway obstruction and snoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation is not necessary to make a diagnosis of peritonsillar abscess, but may help gauge the level of illness and direct therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The laboratory evaluation of a child with peritonsillar infection, therefore, might include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete blood count with differential: the white blood cell count (WBC) is usually elevated with a predominance of polymorphonuclear (PMN) leukocytes, although this is a nonspecific finding.",
"     </li>",
"     <li>",
"      Serum electrolytes if the patient's oral intake has been decreased. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A routine throat culture for group A streptococcus.",
"     </li>",
"     <li>",
"      Gram stain, culture (aerobic and anaerobic), and susceptibility testing of abscess fluid if a drainage procedure is performed. Although these results do not necessarily affect management of uncomplicated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/11\">",
"       11",
"      </a>",
"      ], they may help guide antimicrobial therapy in immunocompromised patients or those with complications or extension of infection. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Drainage'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging is not necessary to make the diagnosis of peritonsillar abscess (PTA), but may be necessary to differentiate PTA from peritonsillar cellulitis and other deep neck space infections and to look for complications. Indications for imaging may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distinguishing cellulitis from abscess: response to a trial of antimicrobial therapy is an alternative to imaging for this indication in patients without airway compromise or other complications. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Overview of approach'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Looking for spread of infection to the parapharyngeal space.",
"     </li>",
"     <li>",
"      Inadequate examination secondary to trismus.",
"     </li>",
"     <li>",
"      Exclusion of other conditions that present with sore throat and signs of respiratory obstruction, such as epiglottitis and retropharyngeal abscess. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computed tomography (CT) with IV contrast is the preferred imaging modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. It distinguishes PTA from cellulitis and also demonstrates the spread of infection to contiguous deep neck spaces. Careful monitoring during transportation and CT scanning is imperative; mild airway distress can be exacerbated by sedation and positioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/24\">",
"     24",
"    </a>",
"    ]. CT should be omitted in children with moderate to severe respiratory distress, particularly when sedation is necessary; such children generally undergo evaluation in the operating room, where if necessary, an artificial airway can be established.",
"   </p>",
"   <p>",
"    On CT with contrast, PTA appears as a hypodense mass with ring enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/25\">",
"     25",
"    </a>",
"    ]. Findings consistent with peritonsillar cellulitis include soft tissue swelling, loss of the fat planes, and lack of ring enhancement.",
"   </p>",
"   <p>",
"    Lateral neck radiographs may be obtained initially to exclude epiglottitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67878 \" href=\"mobipreview.htm?22/26/22958\">",
"     image 1",
"    </a>",
"    ) or retropharyngeal abscess (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63233 \" href=\"mobipreview.htm?23/20/23887\">",
"     image 2",
"    </a>",
"    ) if these conditions have not been excluded clinically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some centers use intraoral ultrasonography to distinguish PTA from cellulitis and to guide needle aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/27-32\">",
"     27-32",
"    </a>",
"    ]. However, intraoral ultrasonography may be limited by trismus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/26\">",
"     26",
"    </a>",
"    ]. PTA appears as an echo-free cavity with an irregular border, and peritonsillar cellulitis appears as a homogeneous or striated area with no distinct fluid collection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging or angiography (MRI or MRA) may better delineate soft tissue involvement and vascular complications in patients with deep neck infections relative to CT. However, these studies have the disadvantage of requiring a patient with potentially compromised swallowing function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    airway patency to lie supine for an extended length of time. Sedation and in young children or patients with airway compromise, anesthesia with endotracheal intubation may be necessary to obtain high quality images. For these reasons, MRI or MRA are seldom used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=see_link&amp;anchor=H988692187#H988692187\">",
"     \"Deep neck space infections\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of peritonsillar abscess (PTA) can usually be made clinically without laboratory data or imaging of any kind in the patient with medial displacement of the tonsil and deviation of the uvula (",
"    <a class=\"graphic graphic_picture graphicRef69943 \" href=\"mobipreview.htm?29/54/30575\">",
"     picture 1",
"    </a>",
"    ). Diagnosis is confirmed by collection of pus at the time of drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/3,33\">",
"     3,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features and imaging cannot always distinguish PTA from cellulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/12,34\">",
"     12,34",
"    </a>",
"    ]. A 24-hour trial of antimicrobial therapy (with or without antecedent imaging) may be helpful in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Failure to respond to a trial of appropriate antibiotic therapy suggests PTA, whereas response to therapy suggests cellulitis. Response is defined by improvement in at least one clinical parameter: sore throat, fever, trismus, or tonsillar bulge. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Imaging'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Needle aspiration'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Suspected PTA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of peritonsillar abscess (PTA) includes other causes of sore throat, upper airway obstruction, and pharyngeal swelling. Clinical features may be helpful in differentiating PTA from these conditions, but in some cases (particularly in young children) imaging",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    examination in the operating room may be necessary to make a definitive diagnosis.",
"   </p>",
"   <p>",
"    Major considerations in the differential diagnosis of PTA include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Epiglottitis",
"      </strong>",
"      &ndash; The classic teaching is that epiglottitis is more rapidly progressive than PTA and occurs in younger children. However, with widespread immunization of infants against Haemophilus influenzae type B, epiglottitis is more commonly seen in older children and adults; in these patients the presentation of epiglottitis may be subtle. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link&amp;anchor=H12#H12\">",
"       \"Epiglottitis (supraglottitis): Clinical features and diagnosis\", section on 'Presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Retropharyngeal abscess or cellulitis",
"      </strong>",
"      &ndash; Retropharyngeal abscess or cellulitis typically occurs in younger children and is associated with minimal peritonsillar findings. Neck stiffness is a prominent feature of retropharyngeal infection and trismus is less common [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"       \"Retropharyngeal infections in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Abscess of the parapharyngeal space",
"      </strong>",
"      &ndash; In patients with abscess of the parapharyngeal space, examination may reveal bulging behind the posterior tonsillar pillar rather than superior to the tonsil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Severe tonsillopharyngitis",
"      </strong>",
"      &ndash; Common causes include Epstein-Barr virus, Herpes simplex virus, coxsackievirus (herpangina), adenovirus, diphtheria, gonorrhea. (See appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overview of approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drainage, antimicrobial therapy, and supportive care are the cornerstones of management for peritonsillar abscess (PTA); peritonsillar cellulitis responds to antimicrobial therapy and supportive care alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/1,6,11,34,36-41\">",
"     1,6,11,34,36-41",
"    </a>",
"    ]. Supportive care includes provision of adequate hydration and analgesia and monitoring for complications.",
"   </p>",
"   <p>",
"    Hospitalization may be necessary, particularly in younger children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/4\">",
"     4",
"    </a>",
"    ]. Older patients with uncomplicated PTA who are well hydrated may be managed as outpatients if they are able to tolerate a drainage procedure and to take oral medications after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prompt surgical intervention is indicated in patients who present with impending airway compromise, complications, enlarging masses, or significant comorbidities (eg, immunodeficiency) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/13,24\">",
"     13,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Drainage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no consensus regarding the optimal initial management for the remainder of patients with suspected PTA who do not require urgent surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/5,11,42\">",
"     5,11,42",
"    </a>",
"    ]. The approach depends upon a number of clinical factors, including the age and cooperativeness of the patient and the degree of certainty of the diagnosis (abscess versus cellulitis). Consultation with an otolaryngologist can help determine appropriate management for the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Probable PTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest needle aspiration or incision and drainage for patients with examination findings consistent with peritonsillar abscess (fever, trismus, voice change, peritonsillar swelling, uvular deviation) who do not have indications for tonsillectomy. Needle aspiration is preferred to incision and drainage if the patient can cooperate. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Needle aspiration'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Incision and drainage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Probable cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest a trial of antibiotics for patients with examination findings consistent with cellulitis who do not have indications for tonsillectomy or urgent surgical intervention. Such patients may respond to a 24 hour trial of appropriate parenteral antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Antibiotic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Suspected PTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;When clinical findings do not clearly differentiate peritonsillar abscess (PTA) from cellulitis, imaging, needle aspiration, or response to antimicrobial therapy can be used to help differentiate the two conditions. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest that patients with suspected PTA and no airway symptoms be admitted to the hospital without imaging (provided that imaging is not necessary to exclude other conditions or complications) for 24 hours of hydration, antibiotics, and analgesia. Surgical intervention (tonsillectomy or incision and drainage) is reserved for those who do not respond to 24 hours of medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/34\">",
"     34",
"    </a>",
"    ]. This strategy was evaluated in a retrospective series of 102 children (8 months to 19 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/35\">",
"     35",
"    </a>",
"    ]. Approximately 50 percent of patients responded to medical therapy and 50 percent underwent tonsillectomy, 80 percent of whom had abscesses at the time of surgery. Children younger than six years were more likely to respond to medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend antibiotic therapy for patients with peritonsillar infection. It is rare for antimicrobial therapy alone to be sufficient to treat a true abscess of the peritonsillar space. However, an initial 24-hour trial of appropriate parenteral antimicrobials is justifiable in patients with presumed peritonsillar cellulitis who show no evidence of airway compromise, septicemia, severe trismus, or other complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/13,34\">",
"     13,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4726203\">",
"    <span class=\"h3\">",
"     Parenteral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric intravenous antibiotic therapy should include coverage for Group A streptococcus, S. aureus, and respiratory anaerobes. Empiric therapy can be amended as necessary based upon culture results if drainage is performed. When tailoring therapy based upon culture results, it is important to bear in mind that peritonsillar abscesses are frequently polymicrobial, and not all microbes are consistently cultured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In areas where S. aureus remains susceptible to methicillin, appropriate antibiotics include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      intravenously (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose [maximum single dose 3 g] every six hours in children; 3 g every six hours in adults),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      intravenously (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose [maximum single dose 600 mg] every eight hours in children; 600 mg every six to eight hours in adults)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In areas with an increased prevalence of community-associated methicillin resistant Staphylococcus aureus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    may still be used. However, if the patient does not respond promptly or if the infection is life-threatening,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be added to the regimen. The recommended dose is [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      intravenously (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose every eight hours in children, maximum single dose 1.5 g, maximum daily dose 4 g; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours in adults, adjusted to obtain a trough level of 15 to 20 mg, maximum single dose 2 g). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'CA-MRSA strains'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4726210\">",
"    <span class=\"h3\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral treatment is maintained until the patient is afebrile and clinically improved. Oral antibiotic therapy should then be continued to complete a 14-day course. Courses shorter than 10 days may be associated with recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate oral regimens for continuation of therapy in areas where S. aureus remains susceptible to methicillin include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      (45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose [maximum single dose 875 mg] every 12 hours in children; 875 mg every 12 hours in adults),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose [maximum single dose 600 mg] every eight hours in children; 300 to 450 mg every six hours in adults)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    has been added to the parenteral regimen, oral therapy can be based upon susceptibility testing of the isolate, if available.",
"   </p>",
"   <p>",
"    If empiric therapy is employed for presumed MRSA infection, regimens can include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose [maximum single dose 600 mg] every eight hours in children; 300 to 450 mg every six hours in adults), unless isolate is resistant.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      (&lt;12 years: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three doses; &ge;12 years: 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two doses in children; 600 mg twice per day in adults; maximum daily dose 1200 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonsillar abscess (PTA) usually requires surgical drainage through needle aspiration, incision and drainage, or tonsillectomy, procedures that are usually performed by an otolaryngologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6\">",
"     6",
"    </a>",
"    ]. Drainage with any of these procedures, in combination with antimicrobial therapy and hydration, results in resolution in more than 90 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6,42\">",
"     6,42",
"    </a>",
"    ]. Given that the procedures are equally effective, the choice of procedure depends upon other factors, such as the skill and experience of the health care provider, age and ability of the patient to cooperate, cost, and whether the patient has indications for tonsillectomy (eg, recurrent acute throat infection). Each procedure has advantages in certain situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An older, cooperative child, teenager, or adult without trismus or a previous history of pharyngitis may be able to undergo a needle aspiration or simple incision and drainage procedure as an outpatient with topical anesthesia or procedural sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6,45-48\">",
"     6,45-48",
"    </a>",
"    ]. However, if the child is young and unable to cooperate, the procedure must be performed in the operating suite. Special care must be taken with the administration of procedural sedation because the risk of airway complication is increased.",
"   </p>",
"   <p>",
"    In the absence of a previous history of recurrent pharyngitis, needle aspiration or incision and drainage may be sufficient. In contrast, if there have been previous episodes of pharyngitis or PTA (either of which predict the possible recurrence of the PTA), then a quinsy tonsillectomy is typically performed. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Tonsillectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle aspiration of peritonsillar abscess (PTA) (",
"    <a class=\"graphic graphic_picture graphicRef61393 \" href=\"mobipreview.htm?10/41/10899\">",
"     picture 3",
"    </a>",
"    ) may be performed in the outpatient setting with topical anesthesia by an experienced clinician (usually an otolaryngologist) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. Ultrasound may be used to guide the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/27,31\">",
"     27,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients generally tolerate needle aspiration better than incision and drainage since it is less invasive and less painful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/11,38\">",
"     11,38",
"    </a>",
"    ]. Needle aspiration is the procedure of choice for children whose general condition is too poor to tolerate a general anesthetic and those with a bleeding diathesis who wish to avoid blood transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized trials comparing needle aspiration to incision and drainage, the procedures had similar success rates (each &ge;92 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/38,42,49,50\">",
"     38,42,49,50",
"    </a>",
"    ]. A meta-analysis found needle aspiration to be 94 percent successful in acute resolution (range 85 to 100 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/11\">",
"     11",
"    </a>",
"    ]. Repeat aspiration may be necessary in 4 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/13,33,38,39\">",
"     13,33,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of needle aspiration may include hemorrhage and aspiration of pus and blood into the airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/51\">",
"     51",
"    </a>",
"    ]. Carotid artery injury has not been reported as a complication of needle aspiration of PTA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6\">",
"     6",
"    </a>",
"    ]; however, catastrophic hemorrhage may result from aspiration of a pseudoaneurysm mimicking PTA or necrosis of the carotid artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Differential diagnosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The patient must be observed after the needle aspiration to make sure he or she can tolerate oral antimicrobial therapy, pain medications, and liquids. If the patient is not admitted to the hospital, he or she should be seen for follow-up in 24 to 36 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Discharge instructions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Incision and drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incision and drainage of peritonsillar abscess is usually performed by an otolaryngologist (",
"    <a class=\"graphic graphic_picture graphicRef50675 \" href=\"mobipreview.htm?14/3/14391\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6\">",
"     6",
"    </a>",
"    ]. In older children, it may be performed in the outpatient setting with topical anesthesia or procedural sedation; general anesthesia is usually required for young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6,33,44-46\">",
"     6,33,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incision and drainage is more painful than needle aspiration and causes more bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6,33\">",
"     6,33",
"    </a>",
"    ]. A second procedure may be required for complete resolution. Complications may include aspiration of the abscess contents.",
"   </p>",
"   <p>",
"    Patients must be observed after the procedure to make sure they can tolerate oral antimicrobial therapy, pain medications, and liquids. Patients who are not admitted to the hospital should be seen for follow-up in 24 to 36 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Discharge instructions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Tonsillectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible indications for tonsillectomy in patients with peritonsillar abscess (PTA) include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/2-4,6,13\">",
"     2-4,6,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant upper airway obstruction or other complications.",
"     </li>",
"     <li>",
"      Previous episodes of severe recurrent pharyngitis or PTA (each of which predicts the possible recurrence of PTA).",
"     </li>",
"     <li>",
"      Other indications for tonsillectomy (eg, chronic symptoms or signs of upper airway obstruction, such as snoring). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=see_link&amp;anchor=H6#H6\">",
"       \"Tonsillectomy and adenoidectomy in children\", section on 'Tonsillectomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35176?source=see_link\">",
"       \"Tonsillectomy in adults: Indications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Failure of the abscess to resolve with other drainage techniques.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If tonsillectomy is required, it may be performed immediately (quinsy tonsillectomy or \"tonsillectomy a chaud\") or after resolution of the acute infection (interval tonsillectomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/2,54-56\">",
"     2,54-56",
"    </a>",
"    ]. Quinsy tonsillectomy avoids the need for repeat hospitalization and anesthesia, and minimizes loss to follow-up, but may be associated with increased risk of bleeding. Interval tonsillectomy may be more difficult technically if there is fibrosis following the acute infection.",
"   </p>",
"   <p>",
"    Tonsillectomy is the most expensive of the drainage procedures, requires general anesthesia and hospitalization, and may delay drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6,33\">",
"     6,33",
"    </a>",
"    ]. In five series involving 1027 patients, the overall incidence of bleeding after quinsy tonsillectomy in children and adults was 1 percent (range 0 to 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/13\">",
"     13",
"    </a>",
"    ]. In the only series confined to children, none of the 55 patients had postoperative or delayed bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/57\">",
"     57",
"    </a>",
"    ]. Additional complications and adverse effects of tonsillectomy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=see_link&amp;anchor=H6#H6\">",
"     \"Tonsillectomy and adenoidectomy in children\", section on 'Tonsillectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6761?source=see_link&amp;anchor=H26#H26\">",
"     \"Tonsillectomy in adults: Surgery\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence regarding the benefits of glucocorticoids in the management of peritonsillar abscess (PTA) is inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/12,58\">",
"     12,58",
"    </a>",
"    ]. In the only randomized trial, glucocorticoids appeared to hasten symptomatic improvement in adolescent (&gt;16 years) and adult patients treated with needle aspiration and intravenous antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/58\">",
"     58",
"    </a>",
"    ]. In a retrospective case series of 249 episodes of PTA in children &lt;18 years, glucocorticoids were used in 37 percent but without clear benefit or adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/12\">",
"     12",
"    </a>",
"    ]. Additional information is necessary before the routine use of glucocorticoids can be recommended in the management of PTA in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Discharge instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are discharged from the emergency department or hospital after treatment for peritonsillar infection should be instructed that prompt reevaluation is necessary for [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Worsening throat pain, neck pain, or trismus",
"     </li>",
"     <li>",
"      Enlarging mass",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Neck stiffness",
"     </li>",
"     <li>",
"      Bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are treated as outpatients should be seen for follow-up in 24 to 36 hours. Those who have been admitted to the hospital should have follow-up within several days of discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment is defined by symptomatic improvement in sore throat, fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tonsillar swelling within 24 hours of intervention.",
"   </p>",
"   <p>",
"    Treatment failure is defined by lack of symptomatic improvement or worsening despite 24 hours of antimicrobial therapy (with or without surgical drainage). Treatment failure may occur in patients who have developed complications, are infected with unusual organisms, or have underlying problems (eg, congenital cyst or tract) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/24\">",
"     24",
"    </a>",
"    ]. Reevaluation of such patients may include repeat imaging (CT with contrast to look for extension of infection) or surgical intervention. Broadening antimicrobial therapy also may be indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis and prompt, appropriate management of peritonsillar infection is critical to avoiding complications. Complications of peritonsillar abscess (PTA) occur rarely, but are potentially fatal. Infection can spread from the peritonsillar space to other deep neck spaces, to adjacent structures, and to the bloodstream.",
"   </p>",
"   <p>",
"    Complications of PTA may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/3,4,13,59\">",
"     3,4,13,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway obstruction",
"     </li>",
"     <li>",
"      Aspiration pneumonia if the abscess ruptures into the airway",
"     </li>",
"     <li>",
"      Septicemia",
"     </li>",
"     <li>",
"      Internal jugular vein thrombosis",
"     </li>",
"     <li>",
"      Jugular vein suppurative thrombophlebitis (Lemierre syndrome) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/60,61\">",
"       60,61",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=see_link&amp;anchor=H990947896#H990947896\">",
"       \"Deep neck space infections\", section on 'Complications'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Carotid artery rupture",
"     </li>",
"     <li>",
"      Pseudoaneurysm of the carotid artery (suggested by recurrent bleeding from the ear, nose, or throat, prolonged course, tachycardia, anemia, or 10",
"      <sup>",
"       th",
"      </sup>",
"      or 12",
"      <sup>",
"       th",
"      </sup>",
"      cranial nerve palsies) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mediastinitis",
"     </li>",
"     <li>",
"      Necrotizing fasciitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sequelae of Group A streptococcus infection (when that organism is isolated) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27110?source=see_link\">",
"       \"Complications of streptococcal tonsillopharyngitis\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With early and appropriate treatment, most peritonsillar infections resolve without sequelae. Recurrence is estimated to occur in 10 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/11,42,44\">",
"     11,42,44",
"    </a>",
"    ]. The risk of recurrence is increased in patients with a history of recurrent tonsillitis before development of the abscess (40 versus 9.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritonsillar abscess (PTA) is the most common deep neck infection in children and adolescents. It occurs most frequently in adolescents and young adults, but can occur in younger children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PTA often is polymicrobial. The predominant bacterial species are Streptococcus pyogenes (group A streptococcus), Staphylococcus aureus (including methicillin-resistant S. aureus), and respiratory anaerobes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical clinical presentation of PTA is a severe sore throat, fever, a \"hot potato\" or muffled voice, drooling, and trismus. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination findings consistent with PTA include an enlarged and fluctuant tonsil with deviation of the uvula to the opposite side (",
"      <a class=\"graphic graphic_picture graphicRef69943 \" href=\"mobipreview.htm?29/54/30575\">",
"       picture 1",
"      </a>",
"      ). Alternatively, there may be fullness or bulging of the posterior soft palate near the tonsil with palpable fluctuance. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation is not necessary to make a diagnosis of PTA, but may help gauge the level of illness and to direct therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging is not necessary to make the diagnosis of PTA, but may be helpful in differentiating PTA from other deep neck space infections and when evaluating for complications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PTA can be made clinically in the patient with medial displacement of the tonsil and deviation of the uvula (",
"      <a class=\"graphic graphic_picture graphicRef69943 \" href=\"mobipreview.htm?29/54/30575\">",
"       picture 1",
"      </a>",
"      ). However, clinical features cannot always distinguish PTA from cellulitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/61/31705/abstract/4,34\">",
"       4,34",
"      </a>",
"      ]. Imaging, aspiration, or a trial of appropriate antibiotic therapy may help make this distinction. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend antibiotic therapy for all patients with suspected peritonsillar infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Empiric therapy should include coverage for Group A streptococcus, S. aureus, and respiratory anaerobes. Therapy should be continued for 14 days. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have examination findings consistent with peritonsillar abscess (swollen, medially deviated, fluctuant tonsil, deviation of the uvula) generally require drainage in addition to antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Overview of approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt surgical intervention is indicated in patients with impending airway compromise, complications, enlarging masses, or significant comorbidities. The approach to the patient who does not require emergent drainage depends upon a number of factors, including age, cooperativeness, and the degree of certainty of the diagnosis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Overview of approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to antibiotic therapy, we suggest needle aspiration or incision and drainage for cooperative patients with examination findings consistent with PTA if they do not have indications for tonsillectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Probable PTA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a trial of antibiotics for patients with examination findings consistent with cellulitis who do not have indications for tonsillectomy or urgent surgical intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Probable cellulitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with suspected PTA and no airway symptoms be admitted to the hospital without imaging (provided that imaging is not necessary to exclude other conditions or complications) for 24 hours of hydration, antibiotics, and analgesia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgical intervention (tonsillectomy or incision and drainage) is reserved for those who do not respond to 24 hours of medical therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Suspected PTA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that tonsillectomy be reserved for patients who fail to respond to other drainage techniques, develop complications, or have other indications for tonsillectomy (eg, previous episodes of PTA or recurrent severe pharyngitis, chronic upper airway obstruction) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Tonsillectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of PTA are potentially fatal. Infection can spread to other deep neck spaces, to adjacent structures, and to the bloodstream. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With early and appropriate treatment, most peritonsillar infections resolve without sequelae. Recurrence is estimated to occur in 10 to 15 percent of patients. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/1\">",
"      Ungkanont K, Yellon RF, Weissman JL, et al. Head and neck space infections in infants and children. Otolaryngol Head Neck Surg 1995; 112:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/2\">",
"      Schraff S, McGinn JD, Derkay CS. Peritonsillar abscess in children: a 10-year review of diagnosis and management. Int J Pediatr Otorhinolaryngol 2001; 57:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/3\">",
"      Galioto NJ. Peritonsillar abscess. Am Fam Physician 2008; 77:199.",
"     </a>",
"    </li>",
"    <li>",
"     Goldstein, NA, Hammerschlag, MR.. Peritonsillar, retropharyngeal, and parapharyngeal abscesses. In: Textbook of Pediatric Infection Diseases, 6th, Feigin, RD, Cherry, JD, Demmler-Harrison, GJ, Kaplan, SL (Eds), Saunders, Philadelphia 2009. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/5\">",
"      Keir, J, Almeyda, R, Bowyer, DJ, et al. Alternative strategies for drainage of peritonsillar abscess (Protocol). Cochrane Database Syst Rev 2006; :CD006287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/6\">",
"      Herzon FS, Martin AD. Medical and surgical treatment of peritonsillar, retropharyngeal, and parapharyngeal abscesses. Curr Infect Dis Rep 2006; 8:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/7\">",
"      Passy V. Pathogenesis of peritonsillar abscess. Laryngoscope 1994; 104:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/8\">",
"      Lehnerdt G, Senska K, Fischer M, Jahnke K. [Smoking promotes the formation of peritonsillar abscesses]. Laryngorhinootologie 2005; 84:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/9\">",
"      Dilkes MG, Dilkes JE, Ghufoor K. Smoking and quinsy. Lancet 1992; 339:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/10\">",
"      Friedman NR, Mitchell RB, Pereira KD, et al. Peritonsillar abscess in early childhood. Presentation and management. Arch Otolaryngol Head Neck Surg 1997; 123:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/11\">",
"      Herzon FS. Harris P. Mosher Award thesis. Peritonsillar abscess: incidence, current management practices, and a proposal for treatment guidelines. Laryngoscope 1995; 105:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/12\">",
"      Millar KR, Johnson DW, Drummond D, Kellner JD. Suspected peritonsillar abscess in children. Pediatr Emerg Care 2007; 23:431.",
"     </a>",
"    </li>",
"    <li>",
"     Yellon, RF. Head and neck space infections. In: Pediatric Otolaryngology, 4th, Bluestone, CD, Casselbrant, ML, Stool, SE, et all (Eds), Saunders, Philadelphia 2003. p.1681.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/14\">",
"      Brook I. Microbiology and management of peritonsillar, retropharyngeal, and parapharyngeal abscesses. J Oral Maxillofac Surg 2004; 62:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/15\">",
"      Inman JC, Rowe M, Ghostine M, Fleck T. Pediatric neck abscesses: changing organisms and empiric therapies. Laryngoscope 2008; 118:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/16\">",
"      Ehlers Klug T, Rusan M, Fuursted K, Ovesen T. Fusobacterium necrophorum: most prevalent pathogen in peritonsillar abscess in Denmark. Clin Infect Dis 2009; 49:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/17\">",
"      Szuhay G, Tewfik TL. Peritonsillar abscess or cellulitis? A clinical comparative paediatric study. J Otolaryngol 1998; 27:206.",
"     </a>",
"    </li>",
"    <li>",
"     Tebruegge M, Curtis N. Infections related to the upper and middle airways. In: Principles and Practice of Pediatric Infectious Diseases, 3rd, Long, SS, Pickering, LK, Prober, CG (Eds), Elsevier Saunders, New York 2012. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/19\">",
"      Simons JP, Branstetter BF 4th, Mandell DL. Bilateral peritonsillar abscesses: case report and literature review. Am J Otolaryngol 2006; 27:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/20\">",
"      Safdar A, Hughes JP, Walsh RM, Walsh M. Bilateral peritonsillar abscess revisited. Ear Nose Throat J 2005; 84:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/21\">",
"      Mobley SR. Bilateral peritonsillar abscess: case report and presentation of its clinical appearance. Ear Nose Throat J 2001; 80:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/22\">",
"      Fasano CJ, Chudnofsky C, Vanderbeek P. Bilateral peritonsillar abscesses: not your usual sore throat. J Emerg Med 2005; 29:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/23\">",
"      Fiechtl JF, Stack LB. Images in clinical medicine. Bilateral peritonsillar abscesses. N Engl J Med 2008; 358:e27.",
"     </a>",
"    </li>",
"    <li>",
"     Beahm, ED, Elden, LM. Bacterial infections of the neck. In: Current Pediatric Therapy, 18th, Burg, FD, Ingelfinger, JR, Polin, RA, Gerson, AA (Eds), Saunders, Philadelphia 2006. p.1117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/25\">",
"      Patel KS, Ahmad S, O'Leary G, Michel M. The role of computed tomography in the management of peritonsillar abscess. Otolaryngol Head Neck Surg 1992; 107:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/26\">",
"      Scott PM, Loftus WK, Kew J, et al. Diagnosis of peritonsillar infections: a prospective study of ultrasound, computerized tomography and clinical diagnosis. J Laryngol Otol 1999; 113:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/27\">",
"      Lyon M, Blaivas M. Intraoral ultrasound in the diagnosis and treatment of suspected peritonsillar abscess in the emergency department. Acad Emerg Med 2005; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/28\">",
"      Boesen T, Jensen F. Preoperative ultrasonographic verification of peritonsillar abscesses in patients with severe tonsillitis. Eur Arch Otorhinolaryngol 1992; 249:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/29\">",
"      Buckley AR, Moss EH, Blokmanis A. Diagnosis of peritonsillar abscess: value of intraoral sonography. AJR Am J Roentgenol 1994; 162:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/30\">",
"      Strong EB, Woodward PJ, Johnson LP. Intraoral ultrasound evaluation of peritonsillar abscess. Laryngoscope 1995; 105:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/31\">",
"      Blaivas M, Theodoro D, Duggal S. Ultrasound-guided drainage of peritonsillar abscess by the emergency physician. Am J Emerg Med 2003; 21:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/32\">",
"      Costantino TG, Satz WA, Dehnkamp W, Goett H. Randomized trial comparing intraoral ultrasound to landmark-based needle aspiration in patients with suspected peritonsillar abscess. Acad Emerg Med 2012; 19:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/33\">",
"      Herzon FS, Nicklaus P. Pediatric peritonsillar abscess: management guidelines. Curr Probl Pediatr 1996; 26:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/34\">",
"      Brodsky L, Sobie SR, Korwin D, Stanievich JF. A clinical prospective study of peritonsillar abscess in children. Laryngoscope 1988; 98:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/35\">",
"      Blotter JW, Yin L, Glynn M, Wiet GJ. Otolaryngology consultation for peritonsillar abscess in the pediatric population. Laryngoscope 2000; 110:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/36\">",
"      Ophir D, Bawnik J, Poria Y, et al. Peritonsillar abscess. A prospective evaluation of outpatient management by needle aspiration. Arch Otolaryngol Head Neck Surg 1988; 114:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/37\">",
"      Savolainen S, Jousimies-Somer HR, M&auml;kitie AA, Ylikoski JS. Peritonsillar abscess. Clinical and microbiologic aspects and treatment regimens. Arch Otolaryngol Head Neck Surg 1993; 119:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/38\">",
"      Stringer SP, Schaefer SD, Close LG. A randomized trial for outpatient management of peritonsillar abscess. Arch Otolaryngol Head Neck Surg 1988; 114:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/39\">",
"      Weinberg E, Brodsky L, Stanievich J, Volk M. Needle aspiration of peritonsillar abscess in children. Arch Otolaryngol Head Neck Surg 1993; 119:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/40\">",
"      Johnson RF, Stewart MG. The contemporary approach to diagnosis and management of peritonsillar abscess. Curr Opin Otolaryngol Head Neck Surg 2005; 13:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/41\">",
"      Hall SF. Peritonsillar abscess: the treatment options. J Otolaryngol 1990; 19:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/42\">",
"      Johnson RF, Stewart MG, Wright CC. An evidence-based review of the treatment of peritonsillar abscess. Otolaryngol Head Neck Surg 2003; 128:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/43\">",
"      Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/44\">",
"      Apostolopoulos NJ, Nikolopoulos TP, Bairamis TN. Peritonsillar abscess in children. Is incision and drainage an effective management? Int J Pediatr Otorhinolaryngol 1995; 31:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/45\">",
"      Bauer PW, Lieu JE, Suskind DL, Lusk RP. The safety of conscious sedation in peritonsillar abscess drainage. Arch Otolaryngol Head Neck Surg 2001; 127:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/46\">",
"      Suskind DL, Park J, Piccirillo JF, et al. Conscious sedation: a new approach for peritonsillar abscess drainage in the pediatric population. Arch Otolaryngol Head Neck Surg 1999; 125:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/47\">",
"      Luhmann JD, Kennedy RM, McAllister JD, Jaffe DM. Sedation for peritonsillar abscess drainage in the pediatric emergency department. Pediatr Emerg Care 2002; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/48\">",
"      Lamkin RH, Portt J. An outpatient medical treatment protocol for peritonsillar abscess. Ear Nose Throat J 2006; 85:658, 660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/49\">",
"      Maharaj D, Rajah V, Hemsley S. Management of peritonsillar abscess. J Laryngol Otol 1991; 105:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/50\">",
"      Spires JR, Owens JJ, Woodson GE, Miller RH. Treatment of peritonsillar abscess. A prospective study of aspiration vs incision and drainage. Arch Otolaryngol Head Neck Surg 1987; 113:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/51\">",
"      Steyer TE. Peritonsillar abscess: diagnosis and treatment. Am Fam Physician 2002; 65:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/52\">",
"      Thomas JA, Ware TM, Counselman FL. Internal carotid artery pseudoaneurysm masquerading as a peritonsillar abscess. J Emerg Med 2002; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/53\">",
"      Blum DJ, McCaffrey TV. Septic necrosis of the internal carotid artery: a complication of peritonsillar abscess. Otolaryngol Head Neck Surg 1983; 91:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/54\">",
"      Lockhart R, Parker GS, Tami TA. Role of quinsy tonsillectomy in the management of peritonsillar abscess. Ann Otol Rhinol Laryngol 1991; 100:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/55\">",
"      Chowdhury CR, Bricknell MC. The management of quinsy--a prospective study. J Laryngol Otol 1992; 106:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/56\">",
"      Fagan JJ, Wormald PJ. Quinsy tonsillectomy or interval tonsillectomy--a prospective randomised trial. S Afr Med J 1994; 84:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/57\">",
"      Richardson KA, Birck H. Peritonsillar abscess in the pediatric population. Otolaryngol Head Neck Surg 1981; 89:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/58\">",
"      Ozbek C, Aygenc E, Tuna EU, et al. Use of steroids in the treatment of peritonsillar abscess. J Laryngol Otol 2004; 118:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/59\">",
"      Goldenberg D, Golz A, Joachims HZ. Retropharyngeal abscess: a clinical review. J Laryngol Otol 1997; 111:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/60\">",
"      Ramirez S, Hild TG, Rudolph CN, et al. Increased diagnosis of Lemierre syndrome and other Fusobacterium necrophorum infections at a Children's Hospital. Pediatrics 2003; 112:e380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/61\">",
"      Goldenberg NA, Knapp-Clevenger R, Hays T, Manco-Johnson MJ. Lemierre's and Lemierre's-like syndromes in children: survival and thromboembolic outcomes. Pediatrics 2005; 116:e543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/62\">",
"      Stevens HE. Vascular complication of neck space infection: case report and literature review. J Otolaryngol 1990; 19:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/63\">",
"      Greinwald JH Jr, Wilson JF, Haggerty PG. Peritonsillar abscess: an unlikely cause of necrotizing fasciitis. Ann Otol Rhinol Laryngol 1995; 104:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/64\">",
"      Wenig BL, Shikowitz MJ, Abramson AL. Necrotizing fasciitis as a lethal complication of peritonsillar abscess. Laryngoscope 1984; 94:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/61/31705/abstract/65\">",
"      Kronenberg J, Wolf M, Leventon G. Peritonsillar abscess: recurrence rate and the indication for tonsillectomy. Am J Otolaryngol 1987; 8:82.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6079 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31705=[""].join("\n");
var outline_f30_61_31705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2591682\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overview of approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Probable PTA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Probable cellulitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Suspected PTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4726203\">",
"      - Parenteral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4726210\">",
"      - Oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Incision and drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Tonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Discharge instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Response to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6079|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/26/22958\" title=\"diagnostic image 1\">",
"      Epiglottitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/20/23887\" title=\"diagnostic image 2\">",
"      Retropharyngeal abscess plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6079|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/4/42053\" title=\"figure 1\">",
"      Peritonsillar space anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/39/7797\" title=\"figure 2\">",
"      Anatomy of the parapharyngeal space",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6079|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/54/30575\" title=\"picture 1\">",
"      Peritonsillar abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/34/41509\" title=\"picture 2\">",
"      Peritonsillar abscess with exudate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/41/10899\" title=\"picture 3\">",
"      Peritonsillar abscess needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/3/14391\" title=\"picture 4\">",
"      Peritonsillar abscess I and D",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27110?source=related_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8632?source=related_link\">",
"      Etiology and clinical manifestations of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35176?source=related_link\">",
"      Tonsillectomy in adults: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6761?source=related_link\">",
"      Tonsillectomy in adults: Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_61_31706="Seborrheic dermatitis scalp";
var content_f30_61_31706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54173%7EDERM%2F76985%7EDERM%2F59104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54173%7EDERM%2F76985%7EDERM%2F59104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis of the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse, fine scaliness of the scalp without underlying erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis of the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Facial seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31706=[""].join("\n");
var outline_f30_61_31706=null;
var title_f30_61_31707="Maintenance dose aminoglycoside";
var content_f30_61_31707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Maintenance dose nomogram for conventional aminoglycoside dosing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Creatinine clearance, mL/min",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        Maintenance dose",
"       </p>",
"       <p>",
"        (percent of loading dose)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose interval, hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;90",
"      </td>",
"      <td>",
"       84",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       76",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       84",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       79",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       72",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       86",
"      </td>",
"      <td>",
"       24",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       24-36",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &lt;20*",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * When the creatinine clearance is below 20 mL/min, a loading dose is recommended with subsequent doses guided by monitoring of the serum aminoglycoside concentration.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31707=[""].join("\n");
var outline_f30_61_31707=null;
var title_f30_61_31708="Symptoms GI lymphoma";
var content_f30_61_31708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms in gastrointestinal lymphoma according to involved site",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stomach (n=277)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Small bowel (n=32)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ileocecal (n=26)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Multiple sites (n=24)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of appetite",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"space\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Night sweats",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constipation",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"space\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perforation",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ileus",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No symptoms",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table shows the percent of patients with the listed symptom at each of the four major sites of disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Koch P, et al. J Clin Oncol 2001; 19:3861.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31708=[""].join("\n");
var outline_f30_61_31708=null;
var title_f30_61_31709="Beta blocker MI COPD";
var content_f30_61_31709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Beta blocker after MI is effective in patients with chronic lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In an analysis of 201,752 patients with an acute myocardial infarction (MI), those with chronic obstructive pulmonary disease (COPD) who received a beta blocker had a significant increase in survival at two years compared to patients with COPD who did not receive this therapy (83.2 versus 72.2 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gottlieb SS, McCarter RJ, Vogel RA. N Engl J Med 1998; 339:489.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31709=[""].join("\n");
var outline_f30_61_31709=null;
var title_f30_61_31710="Gout of the foot x ray";
var content_f30_61_31710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gout of the foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 195px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADDAWEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwIDnFH8qPyooAPrmgEjvijp+VH0/OgAHHTv8AnR/KkpaADPPIH0xRnij2/rRnjrQAfyo/KjsaOhz3oAOpH+c0Z4oo4FABnnn9aPyzRSdvSgBff/8AWaOnb/61HqaD+FAC5yBke3rSA5yTxRn8+9A/OgBykY7f1pAwGTgflxSckUdv8aAHA84PXPQ9jSjbuA689qYcdAD9KP8APSgB6lfT6D3pAAeAcZ68fnSZ4x+ZpQ3TPT+lADiemSD7jqaBkD0255qPPHvRnt19qAJWxwRjAwOehpSVXBGR7iosktkk+9KPl9CPfpQA715BB6cd6eDkjGRzzke1RNjAzxx0p6ADnJI9+AaAHEE9Dwf0p3c5HfvTD1bH1IHH/wCqgA5IU4AFADh8rY6/XtSnrn2x0poHJz279x6UrEHjAPU0AKD1FLSDscUDqQM8e9ACng+lHfpz6UHg+/0o9e1AC9TSDp9OaXuM0g70AKPbHHf0oXHU4x9M0d/akOMCgCZXGAcDNSL6Y6d+tQL8wA5zz0/wp6EbTyNwGM0AO3D3/I0UnP8AtfpRQBnYOM446Un4e9W9meNv1H+NMEIHr/8AWoAr8jtR74qfyfc01o9uSDkfTrQBEfpQep/rTiCCQf1pMH9PSgA79KQngcUuKPx5oATvz1pec9MdqOx5xR36d6AE/ClOeeP8aOf8eaTt0oAM+3FH60vp60UAJz369aO/Sl7UAZ6DNACfhR+tKQe/f1pyqxYDHPoaAGdqD/nNO25PB6DPHP4UoGDjpkYx60AN9sUAEnAGcmpQgwOoHrmlEY3DnJ60AQgEYzjj8acvJAI4+lSqvG3n8KcFHJ4HbHbFAEADEjsTyCacFGSrZGOuam5+gNNKc+n4dDQBGI843cdqUJ/s8gdzUv5UYoAiCZVTz64IpxTLZBI+lPxz/jQcexoAaFAzgD60BfmyOD1wadgdMCkA+YZHPagAAIzg/nz6UBcLjHalHY0cd6AEwMc4/GlIyDn/APVS4I9jSMMdRg0AJjkfTGc0vbpQ3Wjn8TQAv8qSgY7f55oHfigA7j9KO1L3/nSdhQAqnjHb64qRTnjjJHbjtUYPQYpVAPA/Lr2oAk3R+35UUzaP9j8zRQBd8k+ooER45HNdCmi302cWch+q/wCfWnf2DOB86AH65/OgDmDDgj5c89qaIQcfL9DXTPokpGEHzehyM/nUcehXjtgQSc9wOKAOb8j5cjdj1qIwEBgNozx0r0LT/BU9x81xL5SA81Pc+CrbYxtb1ZGxyAOTQB5mYSOoJ+vNNaL+HGPw5rpdS0SewbE0ZK5+8oODWYYum1jjuaAMxo1Oe1AjXjvj3rQMHH3QSevt+NNEOOdp/wD1UAUvKXAwDj1pPKXOefwq9t7469/WlZcZDDj0xQBQEO0gknHcU0Rcdf0rQ25yduffHH+eKayhgeKAKIixjIBOfWnhFHOKttEoPKkYppiHY8+uaAKvlgdBn2oKbsZ5x0HpVjyj/nrigxnjmgCEDA44PqKXHHHSpDGQfxpfK59vbtQBFjk+v60VN5Q5GeaeqBeQPmoAg2t/dNIB6dPWryMvRlHHepHgiZAV5YjmgDMP60uOgq0YMMSBwPyoEBJC7Sc9sUAVB1pVXI46VpCykIOVP4UrWbgEdx+FAGdj/ZHbOOlA+6SQB3zV9rVweh/KkWAb8E4JPpigCmIuOv8AgaYyEHGM49K0ggjJA69OaURh2+7n+n1oAzAhILAcCpIIt546ir0kKruX14z+tT21qNp+TGemDQBnFAW5AJHt3prx7QeCDg1dkjZZTu+6OmabIm7k8Y/SgDNdSrc0n6VcuICVGMEj3qoRjqKADuM0gzzS/wAqXYccYPGeKAEHX6UnYetOC5PXv25pCpC9KAEHanbj2yeMUnGPQe9A/wA+tAC/J/tUVJ5jf3DRQB9dvoFsWliCsjoduAKzJ/CcczZjAJPJOP8AH+deqwWcVyQ5VFYdWXvViPS7dAo2L7+5oA8aHgsp82wPkdAv1rX0XwqkEZnuIiGDZxjAFeorp6LIGDcj0HaoNRt5J4hGoULxg9qAPM9e0m3vwXsUCMo+aOMda4q401vMJijYP/sjBr1640mWJGeECEj+IfxVTutEYky7NuOWIH50AeYPoplhC3EBdSP0/wA/59Mu78C2Nzu2AwynODzj8q9ik00LAMglOOQvzfSsq80n5T5SsuD3x3+lAHjF58MNUAD2nlXCdRt4P+Fc9feC9bsx+9sZiB6Lur6Ato7m1bG7cAOCOv8AnmtKG/d1IuUVwTxkdKAPlaXSb2E4ktpUPcMh/wAKrtbOMZUgY78V9ak2FyoE9pGobuce9Vrjw7oN42JbONCT1IyKAPlAQtkDb04FL5Tjnb/9evqCT4caFdAmKCJhjGV4P5fjWPd/CPTW3eUjr6bTmgD51ki2n5l6d6jaMH27cCvb7z4TpFnYZgOxz+dc/ffDe4gbhmbHZlz/ACoA8sMJHcYHrQIj6gDFd3J4Guw7bRlR3GRVCbw/LCCPKPr0oA5fyl54PH6VHJGFAOeK3pLHyoScEY6jFZEiDJBBGTQBUpyru4Jwc9MVOUwvy4DAcHrTREA3GePzoAYYTzyKlhjfkAbvpS5wdx4FKpIIKnB7EUABGDhhyOop8LbX4OPp6083G4guNxHc9frSMY8krlSDnOM0Aa8JDRHedzZ45705oRj7uAeOTxWZDc4IAyM+prTgnMg25yvpQBTlTDcDbjiqxQDBbb1yT0rSmXDkA59cVSm3MeduaAKZIJLHA74zUkbqEKgkH2FRMpU4IwakjaMKuV5z1oAWbcoUE5HfP+fer8UqpEMryc1SUrI27PCngdKsK2I8HgA5470AI4VwSMY9KpS7dx2jAHFWyB6celVJMB3yTnPpQA05phjU545NPJOR9MUfpQBXMMajJH5cUzaMYHI9j0q2RkjI5/z2piqOcAe/FAEDRkEnbz64zioXT5c5OSfWrrtjIJ9hVVxlcYzmgCFs8Z+mM5NNHQnrTz/dyenQ84pnQZoATcfb8hRSUUAfolaW/ljcWB9CBirXt60CjrigA/H60dBj0o5oJA5JAHvQA10Vx8yg1Wmt8D5epB9Kso6tkg9MA89Ko311iN0jKnjqOhoAxbiBjGABgZPU81kXDKDhsg9Ccn/PWr+oSvFEI0LAnnnpWLdz+dEQcgnjcTQBUe4CKwRgODksM96UvlAxkB4qkQqEktkg8MDn/P8An1o8wsmzcGUDA4oAmJ3jHmEg47U2QyIMB2JHoMf5/wDr/WoVMseCwDK3t/n/AD9afGwcAYDZP1oAntbm4jwGPPUnp+NXYtalTCMxOevHNZrF85CHPbjqKgnd1yW5BXPTp/n3oA6dNcBAjdMjOSfX2qOTUraVD8qtj1Fch9oYjGAe2CantZi77Me5GMYFAGjeYl4CRZIwFPf8e/8A+uuU1K2jLvmIE9AwP+f8/lW5dNJFE7EHYckhjz+H+f8A63Nyl5GBX7vTj/8AV/n9KAMDUtPW43oibX7jPFcXq+leU5xkA8GvSXR5GOcBh0BOP1rntagfZmRAoP4fy/zxQB53JbY6H/AVXIwSCOeldFPa7c9R149qz5rXcSMfjQBmg5NIOBxx9KsTQsGJwAo7f571AwKna2eP0oACR3IpDn8fWpBGxBJ44zz3pnagBCccngDnNX7GXs2fQ8+1Z8mNpzxj8xRFJJE6nA9M0AbsmVQYwA3f/P8AKqE7tgkEA9M9KryXpPXBA6AVE11uIyOPbvQA5jznOfc96T0x+FRiRMDJIp3mJnhj7nFAEkblTjgZxyR0p8Lndt/Ie9Q5GcZGfSmK/wC8I9e9AFl3Hcn7vbgZ+lQkjpn2oJJPPPc881ErEuclvpQBLjBOT39OlAIIz1FRSzrGR39O9RG8cqRgDnOfWgCyTgnJwMYyeAaZlUPTrzUKuDgjgnriml1AOTzQA9mLEZJPt6VGx+U+ncDvQ7ZBx1xkmo2OAvoaAFblQCeM9+tRknJz1/KnegKn6U31xQA2iiigD9HO9H8qPpR70AIxAUljgDrk1jalqRAxCFA9W/Sta4UNGFYEgnGBWfc2yfaCWBJPQDv/AIdKAMN7242lFWP5m5IJBNVrjVMT8kvKM4Cj+ldLFaWxbhFPHG7v9KqXmn28km/YBICOR1B/rQBy97eiRcyrg9c4x+VZM9wmcLgp1PJzz/n/ADmtTWNOuoGy3zIxOCoJP6dKy2s2K7pjjPTJ5x60AMVVbCjkHsw/r/n+dSkIjBdpZh3A61GQiqQnJI6ZpVVXXCx7sjp0/wA/59aAEzyc5B/ugmnAjgHnPUgf5/z9aWC3AZjI6IMc89aX/RxgPcKxPJA/LFAFmBIiuTnJHXGQDSyW6SxkbAwPB2jj8DSLcWSoSrMcevOe1OF9arGVycjtv4/z1oAzW04pIxAAUcZyOPw/CrOnW0AeRpC27A6f1FWXvbaQYKqvPdufzqv9pjQl4AOOeWyP8/59KAJbm1SNXYcnsOv+e36Vzd3bKAXEbKSc8CtPVNejUAlAjn+dc/c6tGyBpHOTxjng+/8An/64BUuFjRs5ySMfKen6/wCf0rI1a5AgKFl255Gf1qlqmrsS+WwCeOf8/wCfwrm7m7aUnJPPqf8APvQBZupbflSwyPfArMlZCQFK+uB/WqN07HOMgCqrEnJyfXNAFuVQAc9AOD2+tVGUMMMOAenvTTPtwCTyOQO1Ridt3zYPr/8AWoAmb7pwM8dDVM8MQeo9atk/Lu5wOcetU3bGWJ5oAGOFyBkjoKrljnJxnsfSpGkwOMHB59Kjd9w5AB9aAGbgTjIz6Uvbn+VQswVuDn24oD5Y88H86AJu+M8/Wk3cgfjnHFRBucZHH5U3OG4OG6HPNAFjt0Iz60+JwrcnrxmqnmdNxPTnHenNLnJXigC2zlX+bkY4FRM4Yk8Z71XZ89h+PNMBIHHpQA6QkvlsU36njpQeuKRjjGDj3xQA7ccDmgZByDzmkHUDvjk0lAD85I6HHFNzkAGlH8+PXFIelAAT2z+falJ7E0gP+fWigBKKKKAP0VjnLOQRtGM5J5/Kp+9ZtuQpBY84wV/wp7XnlxliARzwOcUAX8DPT9KDgnOASKq292s2SCAv171N50fZwe9ADmVWwWAOOc0xbeNWzt/A1Lnv1pCQOpwPegCveWyzwFBheOwrg9d0C6tnMnl+dDycg5I+orv57iOEfMQT6D9KZ58cw2t909eaAPEb/XLexYrtxIDznrWPL4ukMZCxZJ5y3Yf57V7XqvhfTdTT95DFIDwTtrz3xB8NYt8kllIyjqM9KAOBl8RXkrkK+AT2B9qhXWJxkySg/pgVd1HwjqNmT8nmKOc4rnrm3uY1dZY3VhycDr+NAGjJqk7tmOd9rHpxxTG1W7UfLK2B2H9K583GPvAgDn0/So2uW5IbCntxQB0v9uXmVKysDn+IH2q7Fr9zGNsgXBAPTkGuQt7pmIaQ/KOpJ7VavNTUsrBSeMLkdqAN+61kTD94hYeuKzLy8YKTlsEcDOawJNTdWLADkZ9qrf2jIGJJBHYdeaALt3MJ1IyR3GcVhvM4ZueM9OlWGnEue3f5TVR0YEkc980AS8uDnncKglwgJB9+e1MLEMwUAEYINQyl2c5LYzj6YoAi5PHPalGMctg56CgqVxng4z9KT0H6etAFiWUbTtOSRVRz1x26jFP/AFzSMAykHpQBXfGTjtx04ppOOmc1NKgxuHFQ9yKAIpeAcjv2/rUP9PyqxIMoecfrUB6980AGeBR3pO/t3IpucdRwO3X9fzoAdnj6UmQTwaYzfLkYwRjJphkIwOw4oAnJAOD19KTjBPfqagLfMD6U0nP09TQBK0mO2DjgZpu7PoT1GaY3XmlUkcDoaAJlcYwOg6H/AD/KlB+b6VAD68A9RTg2SOP/ANdAE24YB7H+VKfu1GMKRlsex4P09qeOh9+aAFHagd6O3+NFACUUUUAfekN7G5QQsGBOQymp5JVI+UDjtjnP/wCqvPbS6vNOmX7UMKDjcn9f89q6hL6KWFZhtePHJzgg55FAGpHOEX0kB6Gq4mkdwWLbeuM9aXT7i0uG+abEg45+n61rHT1wJEw2ehFAFeO+mjjGx8qBz65pyXtw7hSSSePTNK1o20ZyCeAMdaZHA6zYbqAMnvQBnXsxRnwrAdgO9VF1EoB8x7AsO3oK0rm2LyMzEjA5PcVj3FiTu6A+3UigDZs9YeMLna2e/erLazbzrjIGThjXJtasFAJPHzf59ahNvKgBXLc9qAOluBBMGyRzx9eTWFf6Pa3CktCnOck4ziqDXE0Q+Xf+HHNSxai4IycccgkY+n+f8KAOL1jwZbyvIYjsPuOnf/P/AOuuK1LwrdWpLJhhn05Ar2eW4VshmBPuBxVK6ihlBGAT154oA8LuIJbVNs0TKfeq/l+cv3gCOAD0PtXrmqaDBOuDGGB7cdK5i88KIFcRkoewxn/P+fxAPPJkKAiQH/GqpBAGeBXTanod7bgg5kSueniaNtrqVx0zQBD6fzpwkb+Lkdx7U3oevSkPtQA9lVun5elIsbFyBhvTBpjd/mAH/wBelFz5ZwCTQA28hKyKO54pyWqEHLE/SkkdLhtw+Vh0HemyS7OAAe5HSgBJkWNTtUH3Iziqsh2gnv709juYk9fyppGRjP40ARSSFsgZ565qI+9PkBBxkkHtTPf+VADZM4yDg/So3QcdAD+YqXtxwfWmIuG55wTigCMJnOM7h60piyB09Oam4K8d6Xoe/wBKAKbRr0YVE8eOUz75q865yeCR0FMMLcnt60AUMfhSdqkmTa/Ix7Uz19aAEPWjtQaO/vQA4Zzz17mhPXIHrSDt/wDrpUI3YBwKAJV4BBxzxgdc07lk54yOcGouOTu7fpUoGRyCB0xQA4Uf59KQdh70o70AJRRRQB953emK6F2jVgTnOKyZdGNlva3JWGTjbyQPwrs0U+WS77kIzj0qlqMI+z7YgUPHGM/lQBx62LiXarqp6hS20j6HuKv2muSac3lTvGyjoGIz+FXLCVJm8qaISIp4LZOB7Grt7omiX6hZoMA9lYigBI/FVk8ZYow9cc5q1aa3pt2xCTIrYPDcYrmrnwTo6km3uLuNjwB5tc9q3h2e3GY7mQpkgNzken+f8kA9N86xKgfaYzzwdwpwgtJUwJEIIzwR0r501c6lp0xzcT7ckhwx5qnb6zqfnpHHfTI5PPz9OKAPpG402AjPBI6gHmsm708D5k+vSvH38W67YqMXrSKVBUt1xVi2+J2pRkC6iSVT1Kkg4oA767tGUkiMbPQVmzW7cZBGc8f561i23xItZV/fxNGemCKvL4p0++ICzRj2JoAdOhGSMk96pS3Jjf5snHXIFX/t1vICVlUn2amMsE4xuB9eKAM/+0WQcAAkEe3pTX1C3K/PEDkcmprnSw6FkcMvNY9xYSoTjnHOB3/z/nNADbmSymU88n1Gaw7zRbS7DcoQegzVi5hdc8EMORg/5/z+mbM0inO4gDt3H+f8+wBi6h4TZDmEMpz26f8A1qwbvRry24aMnHoOfyrt4tUnjADlX+ozVlNQimOJIgRg54AoA8pnWRXOVYcYxjv7j8KjSCRhwpC+9epzLpzx7ktkds9GGcfhWBfRLI+5I0GOyjH5UAcY0B7HJ9CKicMp+Ydec+tb08an+AZHT9P/AK1VyQIyoVeeelAGQQV4Ix7Gjbv+XjnpmrzJkEEcemaggCiYq/54/X+tADWsy4BDDHvxVd7WRcjggc8VsSQGNuTlQfzqdSsQDBVPTr2oA5nBJ759qfHbTS8pGx/Cuqa4ilG7yYlIHLBetVZLkc/MAQOwoAyYtLnf7wCA+pyasDTooyokk3N6DvU3ns2RnNLvGVbOCevfigCvcwIgwnTt6VQnIAwQSemfStKTuWJIPqetZkzDcByAKAKVzncDgY/Q+1VGQg4HIxnJ4q9dYEo28D61XfBBHPI7CgCuetHbHapCgbj7p9ximtGVxx1oAaPfgf8A16FyMc496fyRjdk98HikUYO4HOO/4UAOj68gZz196l4xntUSBsKR83PI981ICORnHtQA7t/jRSL70v8An0oASiiigD7/ALXUAh2scoe5xwcVDqk7MgMZznviudsdREkRSXKt69vpVr7TuJMTg47Bs7vz/GgCcTxRx4PDDr+J4z+tRy6gqldhx7Z69KybuUSOfMQK3oM/y/z+tVg+5SEJ8z0OeaANhdTAY+ZuI961rC8gkjCybGjfjbnkH1rgLi5kibbsGc8HJ4PWnDUXVs8g+3+fagDttX8M2V7DvQJgnGCRiuG1X4fRCQtCzRtkYK/pWwmuSRWyB5Dg/wAOadD4lTID5x0xzQBxmp+Fb1oCQ6u2MHI5JrkL3Qr+IkGAMR1xXuD6jZ3MfDhWIHDY61lXdnHLnqwPI70AeE3UckIwyMje61WMpPTAPt3r1/UdDhnA75z14rktU8I7SWjzkdhQBxguZU/1czgjJ4YipU1q/jACXUmAc1av9Buoi20Fv6isea2mjJDxMD/u0Aa8Pi/VLcgGbeB6irsXjq6U4kiDdiQa4+TIbvx3/rUMhYDjjHcdKAO9TxxaynFxCw9eM/hVy31rRrsY8xUIxjsa8v5/TFGT260AeoPY21ySba4jJ/u5FZd1Zy2ud8ZC/wA/x/z/AI8IuoXMPyq7AYwOcGtvRvFl5BmG8AuYGHIfsPagDX+0A7gpJOPrg1E8oJIYBm7Y7f41JNJbXMTT2bZUjlCfmX61m3EwL529uaAFusS7jjnrg1nXAUJwR7ZqWSQ9Qfm7GoGkY845oAiK5IJPTt6VUuEK3C4P3verPm4PzjB71XvyvmRhugzmgDQ3tJYoRyy5U+3pVVpewAP8qsW5C2jdclvy4qpc78naDkcDNAEVxLlSN2COwqDLsdud2Oen+fWpIbV5Dk/KgHLZqO5uUQNFAoB6bqAJ9sUA3TPgY+6B+tRNf268gFvx4NZk3zHc5LGoWGDyTn1oA0J9Q8zJGPXp1/xqs04duTtxxVbP4U3nHOR/MUASykF8+nFQPnDYxkjn3pxJ2/KBk1CSODj2/GgAZs5xxxjGeOvapFORhhgf1qMjJIzge9OyMjpgj6CgB6qN/cd8+vNJtwOMZB49KcvqRx2pV4bOMGgAI6AjnFA5XkEU49R0B/Kmnt60AKO1A70dv8aKAEooooA+xEgmVVyCR1BHI/P/AD0qG4WQICmVp9jO0kaBjhgB8hOKvQnOflLjpye1AGXBqM0LlJyHjz0bkgVfVkm5hRWfGOvNLd6Sk4JhkVS3Bz+tYV3HeaY2x0O08gk5FAFu5gZ1wAGwOjHFUxAU5Ccjg4/z/n+Whp2twzALdbfM961Rb2lwf3d0it/dbHP0oA5K7mZW+7kY6n/P+f5ZzBnBIGPoMf4f5/Xt59K5PzIc9G74qi+krjqgA7g4oA5KSaRWxvLfU/5/z+VJBqtzDwJCB3z/AJ/z/Pem0fJba5VRxjvms+bSJV/1bbh2II/z/n8wCNNdmHU9e5HP+f8APtViPWY5iBKoGehBxWRPZSqx9fRhj/P+fwzp7OZXOwNnrweKAOnm+y3Clgy569ef89KyrnTYmB3ICPU1jNNLGB5uenXH+fenwaq6cK+Ow+agCK+0G3lOTGAeucVz97oDIzGLPTgYyK6wawz4Lhc+wzn8qik1GBj8y8H+4c/5/wA/iAeeXFg8P+si4HcDj/P+NU2RQpxnOOg7V6Qws7skM2M9iao3vhq2ucsmCTyGU/4UAedvC25ju6/5/wAKYqSK2QOfrXVXnh6W3J2Pu6nBGawZbe6icqYCQPQGgBtpdSQyqVDAdOP8K0GmiwpLqWPPynH481mPHJkmRdnUDnkVHJCx5BJPAwe1AGz9ptDHn53OMYU8VTlnVs5Xj1/z+FZR/XOMelJndwD8x4FAF+WZEGchAPzqqf3kpJOAePb2qFLZnzuPPvUn2G5Vv3aF/wDd5zxQBsRyKEVGGQuOBUxhQgn9DWZDZ38ZBNs2MjkjpWrJDcSQqZECkYHLUAZmq3CxRmGPhm5NY3fGK3pdKVgZJJQWPJxURtY4wQq/UnFAGQIiwwRg9PekaA7sjLYHU1dlGCQRz7DGeKYTjk//AFqAMuQbXYYwM4pjD3I+laUcXmb5GHHTmonRCSGUr9B/nNAFArgjJGM9P/r1CRxu7HgdqtyIFwCQfWq7Bcsdp47ev+cGgCNhz/8AWpVOMnJ6f5/rQRyQD9OaUc8sffpnmgB8eRnB5A559/Wnoc5Iz6c1GqkYwTn6U5DgDPfmgCQY7UHpTQw3YBGAOfWnZyOOlAAKP8+lA/Wj+VACUUUUAfWSERsGDfNz3rTtb5Qo3L+tc7NvTb5hJcc49P8AP+fZ63ZTI2kjOeT/AI/5/lQB1C6hFG6/KwGeoOfzqzMbS/t/JmIIz8uTgqa5QOW+8RHnJwTyKuC+gjKBXZvUjigDB8SaJeWrsbMbucK49PpXnd3LqdpM6XElxE2eTk4r26PUYiArGJ17B+fyqlrOl2eoqXZFJYZ2jnPpQB5LDr2q20ZEV/KIuBktx+VRN4u1jdn7WRjviug1nwihcmIOg7KD0/z/AJ9uSv8Aw/cwklckehFAFoeNtYGMz5/3h/WrcHju+UjzkyT94qcE1x9xBcQMfMiIA9arF2yRnj0oA9Ej8do3EoYA9c881Zi8ZWEgGQqse3SvL6QkDqRk9vX2oA9bXxHp0wwzRMDn73elkj0q45RgpPA5z/n/AD715C0uwkjk4yMHk0JfTIw8t2Ud8NQB6bc6au4+RIGWsy6tZkBABJPqeDXGx63focpO3fqc4q/B4pulI84B+aANUtcRjaQQfcZqJNRuITgMevY9aWHxRbylVuYRj1x/n/IqwjaZqDER3KK/ZWODQA+PWJSMs2QOM8ZqG41NWJUen3sf5/z9KhvtOltAGPAI654I9jWewA6np3zigBkuS7NkcegqBmjXh0XPQkcf5/8ArUO2zGPWopXDHI6kdRQATLCwyFAbtxnNVZo8HcgHGMY7/wCeKl/z/n86nIMkDZ6MO3agBkCCWIODyMEgdTViGV8/Mvyjoar6e4ikXI4KnPp0qZ3Uq29sEdvb6UAXH1GQjbG5UdM5/nVS6lYnJkYkjPBqDeqn5FGccE0/yNxJ4AHX60AR+ax4yTz2OKkKLtDEEDgjPFMmktoBnzPMYdu3FVLnUt64WMYHrQAyYgtwpB/nVeUHYMclj+fsKRrosQH5P5VFLMG2YxnPOOcigC0X2RqgOF9u9VpWBYnt/OlmkBPJ4A4qBpBkYHbqOKAIZS3P8R9j1+lVmIzxnHTnrU8pAGMnB/lURGMdf6f59qAEA9uOg71LjsB06ZHekCZk5HA7e9O24YFQMdD7UANU85PUdfXHrSnLDcCNvTpS7DxzxS4yO+T+poARV+bIzz1Hc070Jo7HHNHSgA5x/niijFHrnrQAlFFFAH0tK7EHLN0Hf2H+NFq7Fjknon6miigB1yzLK+GPB9c+tR3bFZZcE8AYoooAjE0jw72YltwGaVLy4R1CysOcfzoooA3Sxe3Vm5YjJP61i6rEm8jaMf8A66KKAOcvYY90nyD1/l/ia5jWbO3AZhEoPHTj0oooA5GdiCMHqvP60xh+8UdsL/IUUUAMycY7Up4A+lFFACkfOw7DNJ/CT3oooAjdiCcH3/nUg5X/AICD/KiigDp9AuZrq0aC4kMkUanarc471VuOB+GKKKAKDk4HP+cCo5CRIq9i4FFFACQEuo3c5bH8qkyRDIwPO0/0oooAZYcl89sGnH5lO7nnvRRQA61G6cBuQZCKg1CRycbjjHTt1NFFAGcwwqY7j+pprkhMjrjNFFADXGJCo+7np+dQnhmxxjke3NFFAEjcFiOvT9Kix+8x2zRRQBC3zOFPTP8ASiMfuw38W7GfyoooAeoC9BSMSGUDoaKKAH5pB0P1/wAKKKAHYG5R24puTRRQArcMR2HFB4PHoKKKAEooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the foot demonstrating features consistent with gout. There is soft tissue swelling and extensive erosions involving the first metatarsophalangeal joint, as well as calcifications within a tophus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31710=[""].join("\n");
var outline_f30_61_31710=null;
var title_f30_61_31711="Asthma prevalence age 2006";
var content_f30_61_31711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Current asthma prevalence percents by age, United States: National Health Interview Survey, 2006",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"8\">",
"        Age (years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        All ages",
"       </td>",
"       <td class=\"subtitle2\">",
"        Children",
"       </td>",
"       <td class=\"subtitle2\">",
"        Adults",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        15 - 34",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Total",
"       </td>",
"       <td class=\"subtitle3\">",
"        Age &lt;18",
"       </td>",
"       <td class=\"subtitle3\">",
"        Age 18+",
"       </td>",
"       <td class=\"subtitle3\">",
"        0 - 4",
"       </td>",
"       <td class=\"subtitle3\">",
"        5 - 14",
"       </td>",
"       <td class=\"subtitle3\">",
"        15 - 34",
"       </td>",
"       <td class=\"subtitle3\">",
"        15 - 19",
"       </td>",
"       <td class=\"subtitle3\">",
"        20 - 24",
"       </td>",
"       <td class=\"subtitle3\">",
"        25 - 34",
"       </td>",
"       <td class=\"subtitle3\">",
"        35 - 64",
"       </td>",
"       <td class=\"subtitle3\">",
"        65+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Total:",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"       <td>",
"        10.9",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        11.0",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        13.3",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        8.9",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"       <td>",
"        10.6",
"       </td>",
"       <td>",
"        9.6",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"       <td>",
"        9.1",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        White Non-Hispanic:",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        8.8",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        10.1",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        9.4",
"       </td>",
"       <td>",
"        8.7",
"       </td>",
"       <td>",
"        8.1",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        12.6",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female",
"       </td>",
"       <td>",
"        8.8",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        10.5",
"       </td>",
"       <td>",
"        11.1",
"       </td>",
"       <td>",
"        11.8",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        9.1",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Black Non-Hispanic:",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"       <td>",
"        12.7",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        8.9",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        8.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        14.2",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        17.1",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"       <td>",
"        9.9",
"       </td>",
"       <td>",
"        5.6*",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        8.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        12.9",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"       <td>",
"        12.6",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        9.9",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Other races Non-Hispanic:",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        6.9*",
"       </td>",
"       <td>",
"        8.7*",
"       </td>",
"       <td>",
"        4.5*",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        6.0*",
"       </td>",
"       <td>",
"        7.7*",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        8.1",
"       </td>",
"       <td>",
"        5.4*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        7.9*",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"       <td>",
"        8.2*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Hispanic:",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        10.6",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        11.8",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"       <td>",
"        8.1",
"       </td>",
"       <td>",
"        13.5",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"       <td>",
"        9.7",
"       </td>",
"       <td>",
"        3.4*",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td>",
"        2.4*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Puerto Rican:&Delta;",
"       </td>",
"       <td>",
"        17.2",
"       </td>",
"       <td>",
"        25.7",
"       </td>",
"       <td>",
"        13.1",
"       </td>",
"       <td>",
"        23.9",
"       </td>",
"       <td>",
"        27.3",
"       </td>",
"       <td>",
"        15.7",
"       </td>",
"       <td>",
"        17.7*",
"       </td>",
"       <td>",
"        21.0*",
"       </td>",
"       <td>",
"        11.7*",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        14.6*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male",
"       </td>",
"       <td>",
"        14.5",
"       </td>",
"       <td>",
"        32.4",
"       </td>",
"       <td>",
"        5.6*",
"       </td>",
"       <td>",
"        36.5",
"       </td>",
"       <td>",
"        36.2",
"       </td>",
"       <td>",
"        7.5*",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        5.5*",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female",
"       </td>",
"       <td>",
"        19.7",
"       </td>",
"       <td>",
"        18.9",
"       </td>",
"       <td>",
"        20.1",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        20.2",
"       </td>",
"       <td>",
"        24.3",
"       </td>",
"       <td>",
"        26.8*",
"       </td>",
"       <td>",
"        33.8",
"       </td>",
"       <td>",
"        17.2*",
"       </td>",
"       <td>",
"        18.2",
"       </td>",
"       <td>",
"        21.7*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Mexican/Mexican-American:&Delta;",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        8.8",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"       <td>",
"        3.6*",
"       </td>",
"       <td>",
"        3.8*",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        3.8*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        9.1",
"       </td>",
"       <td>",
"        2.9*",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        11.9",
"       </td>",
"       <td>",
"        4.4*",
"       </td>",
"       <td>",
"        7.7*",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        2.1*",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        6.3*",
"       </td>",
"       <td>",
"        3.2*",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Region:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Northeast",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        13.4",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        10.9",
"       </td>",
"       <td>",
"        11.4",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Midwest",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        10.1",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        South",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        West",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        10.7",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Ratio of family income to poverty threshold:&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 - 0.99",
"       </td>",
"       <td>",
"        11.7",
"       </td>",
"       <td>",
"        12.2",
"       </td>",
"       <td>",
"        11.4",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"       <td>",
"        14.0",
"       </td>",
"       <td>",
"        10.7",
"       </td>",
"       <td>",
"        14.1",
"       </td>",
"       <td>",
"        11.3",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        13.2",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1.00 - 2.49",
"       </td>",
"       <td>",
"        8.1",
"       </td>",
"       <td>",
"        9.4",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"       <td>",
"        11.0",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        9.1",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.50 - 4.49",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        8.9",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4.50 and above",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All relative standard errors are &lt;30 percent unless otherwise indicated.",
"    <div class=\"footnotes\">",
"     * Relative standard error of the estimate is 30-50 percent; the estimate is unreliable.",
"     <br>",
"      &bull; Relative standard error of the estimate exceeds 50 percent.",
"      <br>",
"       &Delta; As a subset of Hispanic.",
"       <br>",
"        &loz; Missing responses imputed.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     National Health Interview Survey, National Center for Health Statistics, Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_61_31711=[""].join("\n");
var outline_f30_61_31711=null;
